Search Results For:

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [agreement-type] => Array
                (
                    [0] => license-agreement
                )

        )

    [filters] => Array
        (
            [agreement] => Array
                (
                    [agreement-type] => Array
                        (
                            [0] => license-agreement
                        )

                )

        )

    [child_filters] => Array
        (
        )

    [agreement_args] => Array
        (
            [post_type] => agreement
            [posts_per_page] => -1
            [tax_query] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => agreement-type
                            [field] => slug
                            [terms] => Array
                                (
                                    [0] => license-agreement
                                )

                        )

                )

        )

    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [tax_query] => Array
                (
                )

            [meta_query] => Array
                (
                    [relation] => OR
                    [0] => Array
                        (
                            [key] => agreement
                            [value] => "1087"
                            [compare] => LIKE
                        )

                    [1] => Array
                        (
                            [key] => agreement
                            [value] => "1084"
                            [compare] => LIKE
                        )

                    [2] => Array
                        (
                            [key] => agreement
                            [value] => "9033"
                            [compare] => LIKE
                        )

                    [3] => Array
                        (
                            [key] => agreement
                            [value] => "1088"
                            [compare] => LIKE
                        )

                    [4] => Array
                        (
                            [key] => agreement
                            [value] => "1090"
                            [compare] => LIKE
                        )

                    [5] => Array
                        (
                            [key] => agreement
                            [value] => "1039"
                            [compare] => LIKE
                        )

                    [6] => Array
                        (
                            [key] => agreement
                            [value] => "4467"
                            [compare] => LIKE
                        )

                    [7] => Array
                        (
                            [key] => agreement
                            [value] => "4794"
                            [compare] => LIKE
                        )

                    [8] => Array
                        (
                            [key] => agreement
                            [value] => "11245"
                            [compare] => LIKE
                        )

                    [9] => Array
                        (
                            [key] => agreement
                            [value] => "3817"
                            [compare] => LIKE
                        )

                    [10] => Array
                        (
                            [key] => agreement
                            [value] => "9858"
                            [compare] => LIKE
                        )

                    [11] => Array
                        (
                            [key] => agreement
                            [value] => "9849"
                            [compare] => LIKE
                        )

                    [12] => Array
                        (
                            [key] => agreement
                            [value] => "4832"
                            [compare] => LIKE
                        )

                    [13] => Array
                        (
                            [key] => agreement
                            [value] => "11464"
                            [compare] => LIKE
                        )

                    [14] => Array
                        (
                            [key] => agreement
                            [value] => "3373"
                            [compare] => LIKE
                        )

                    [15] => Array
                        (
                            [key] => agreement
                            [value] => "1099"
                            [compare] => LIKE
                        )

                    [16] => Array
                        (
                            [key] => agreement
                            [value] => "1083"
                            [compare] => LIKE
                        )

                    [17] => Array
                        (
                            [key] => agreement
                            [value] => "11343"
                            [compare] => LIKE
                        )

                    [18] => Array
                        (
                            [key] => agreement
                            [value] => "1103"
                            [compare] => LIKE
                        )

                    [19] => Array
                        (
                            [key] => agreement
                            [value] => "3888"
                            [compare] => LIKE
                        )

                    [20] => Array
                        (
                            [key] => agreement
                            [value] => "1085"
                            [compare] => LIKE
                        )

                    [21] => Array
                        (
                            [key] => agreement
                            [value] => "3404"
                            [compare] => LIKE
                        )

                    [22] => Array
                        (
                            [key] => agreement
                            [value] => "1092"
                            [compare] => LIKE
                        )

                    [23] => Array
                        (
                            [key] => agreement
                            [value] => "11094"
                            [compare] => LIKE
                        )

                    [24] => Array
                        (
                            [key] => agreement
                            [value] => "5110"
                            [compare] => LIKE
                        )

                    [25] => Array
                        (
                            [key] => agreement
                            [value] => "3794"
                            [compare] => LIKE
                        )

                    [26] => Array
                        (
                            [key] => agreement
                            [value] => "4026"
                            [compare] => LIKE
                        )

                    [27] => Array
                        (
                            [key] => agreement
                            [value] => "1091"
                            [compare] => LIKE
                        )

                    [28] => Array
                        (
                            [key] => agreement
                            [value] => "11063"
                            [compare] => LIKE
                        )

                    [29] => Array
                        (
                            [key] => agreement
                            [value] => "11038"
                            [compare] => LIKE
                        )

                    [30] => Array
                        (
                            [key] => agreement
                            [value] => "11099"
                            [compare] => LIKE
                        )

                    [31] => Array
                        (
                            [key] => agreement
                            [value] => "11079"
                            [compare] => LIKE
                        )

                    [32] => Array
                        (
                            [key] => agreement
                            [value] => "2420"
                            [compare] => LIKE
                        )

                    [33] => Array
                        (
                            [key] => agreement
                            [value] => "5267"
                            [compare] => LIKE
                        )

                    [34] => Array
                        (
                            [key] => agreement
                            [value] => "11325"
                            [compare] => LIKE
                        )

                    [35] => Array
                        (
                            [key] => agreement
                            [value] => "1086"
                            [compare] => LIKE
                        )

                    [36] => Array
                        (
                            [key] => agreement
                            [value] => "4070"
                            [compare] => LIKE
                        )

                    [37] => Array
                        (
                            [key] => agreement
                            [value] => "1089"
                            [compare] => LIKE
                        )

                )

        )

    [text_agreement_args] => 
    [text_provision_args] => 
    [agreement_ids] => Array
        (
            [0] => 1087
            [1] => 1084
            [2] => 9033
            [3] => 1088
            [4] => 1090
            [5] => 1039
            [6] => 4467
            [7] => 4794
            [8] => 11245
            [9] => 3817
            [10] => 9858
            [11] => 9849
            [12] => 4832
            [13] => 11464
            [14] => 3373
            [15] => 1099
            [16] => 1083
            [17] => 11343
            [18] => 1103
            [19] => 3888
            [20] => 1085
            [21] => 3404
            [22] => 1092
            [23] => 11094
            [24] => 5110
            [25] => 3794
            [26] => 4026
            [27] => 1091
            [28] => 11063
            [29] => 11038
            [30] => 11099
            [31] => 11079
            [32] => 2420
            [33] => 5267
            [34] => 11325
            [35] => 1086
            [36] => 4070
            [37] => 1089
        )

    [agreement_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => agreement-type
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => license-agreement
                                        )

                                )

                        )

                )

            [query_vars] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => agreement-type
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => license-agreement
                                        )

                                )

                        )

                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [orderby] => title
                    [order] => ASC
                    [ignore_sticky_posts] => 
                    [suppress_filters] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [taxonomy] => agreement-type
                    [term] => license-agreement
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => agreement-type
                                    [terms] => Array
                                        (
                                            [0] => license-agreement
                                        )

                                    [field] => slug
                                    [operator] => IN
                                    [include_children] => 1
                                )

                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                            [0] => wpry_term_relationships
                        )

                    [queried_terms] => Array
                        (
                            [agreement-type] => Array
                                (
                                    [terms] => Array
                                        (
                                            [0] => license-agreement
                                        )

                                    [field] => slug
                                )

                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => 
			SELECT   wpry_posts.*
			FROM wpry_posts  LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id)
			WHERE 1=1  AND ( 
  wpry_term_relationships.term_taxonomy_id IN (284)
) AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
			GROUP BY wpry_posts.ID
			ORDER BY wpry_posts.post_title ASC
			
		
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 1087
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:27:18
                            [post_date_gmt] => 2020-05-21 20:27:18
                            [post_content] => 
                            [post_title] => AbbVie - MPP, HIV Antiretroviral License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-abbvie-license-agreement-lpv-r
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:59:26
                            [post_modified_gmt] => 2023-09-18 11:59:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1087
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 1084
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:23:34
                            [post_date_gmt] => 2020-05-21 20:23:34
                            [post_content] => 
                            [post_title] => AbbVie - MPP, HIV Antiretroviral Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-abbvie-sublicense-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:59:38
                            [post_modified_gmt] => 2023-09-18 11:59:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1084
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 9033
                            [post_author] => 5
                            [post_date] => 2023-03-03 10:59:48
                            [post_date_gmt] => 2023-03-03 10:59:48
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-03 10:59:48
                            [post_modified_gmt] => 2023-03-03 10:59:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9033
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 1088
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:28:31
                            [post_date_gmt] => 2020-05-21 20:28:31
                            [post_content] => 
                            [post_title] => BMS - MPP - Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-bms-aurobindo-sublicense-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:59:54
                            [post_modified_gmt] => 2023-09-18 11:59:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1088
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 1090
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:31:01
                            [post_date_gmt] => 2020-05-21 20:31:01
                            [post_content] => 
                            [post_title] => BMS - MPP Sublicense & Tech Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-bms-sublicense-tech-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:01:14
                            [post_modified_gmt] => 2023-09-18 12:01:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1090
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 1039
                            [post_author] => 6
                            [post_date] => 2020-05-20 21:10:05
                            [post_date_gmt] => 2020-05-20 21:10:05
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-08-20 12:23:37
                            [post_modified_gmt] => 2021-08-20 12:23:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1039
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 4467
                            [post_author] => 5
                            [post_date] => 2022-03-17 10:56:00
                            [post_date_gmt] => 2022-03-17 10:56:00
                            [post_content] => 
                            [post_title] => Cellscript - BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-17 10:56:00
                            [post_modified_gmt] => 2022-03-17 10:56:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4467
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 4794
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:39
                            [post_date_gmt] => 2022-05-23 13:54:39
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:53:50
                            [post_modified_gmt] => 2023-09-18 11:53:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4794
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 11245
                            [post_author] => 5
                            [post_date] => 2023-09-18 08:29:10
                            [post_date_gmt] => 2023-09-18 08:29:10
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 08:29:10
                            [post_modified_gmt] => 2023-09-18 08:29:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11245
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 3817
                            [post_author] => 6
                            [post_date] => 2021-09-15 10:46:18
                            [post_date_gmt] => 2021-09-15 10:46:18
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-and-gsk-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:16:37
                            [post_modified_gmt] => 2022-10-11 12:16:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3817
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 9858
                            [post_author] => 5
                            [post_date] => 2023-04-14 11:42:47
                            [post_date_gmt] => 2023-04-14 11:42:47
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-20 08:16:24
                            [post_modified_gmt] => 2023-04-20 08:16:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9858
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 9849
                            [post_author] => 5
                            [post_date] => 2023-04-14 11:41:02
                            [post_date_gmt] => 2023-04-14 11:41:02
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-18 13:30:57
                            [post_modified_gmt] => 2023-04-18 13:30:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9849
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 4832
                            [post_author] => 5
                            [post_date] => 2022-05-27 13:18:02
                            [post_date_gmt] => 2022-05-27 13:18:02
                            [post_content] => 
                            [post_title] => Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-27 13:18:02
                            [post_modified_gmt] => 2022-05-27 13:18:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4832
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 11464
                            [post_author] => 5
                            [post_date] => 2023-11-15 09:55:17
                            [post_date_gmt] => 2023-11-15 09:55:17
                            [post_content] => 
                            [post_title] => GARDP – Orchid Pharma Ltd., Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-pharma-ltd-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-15 09:55:17
                            [post_modified_gmt] => 2023-11-15 09:55:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11464
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 3373
                            [post_author] => 5
                            [post_date] => 2021-06-30 16:31:33
                            [post_date_gmt] => 2021-06-30 16:31:33
                            [post_content] => 
                            [post_title] => Gates Foundation - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:17:38
                            [post_modified_gmt] => 2022-10-11 12:17:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3373
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 1099
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:39:09
                            [post_date_gmt] => 2020-05-21 20:39:09
                            [post_content] => 
                            [post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-indian-manufacturers-hcv-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:09:20
                            [post_modified_gmt] => 2021-09-15 12:09:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1099
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 1083
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:22:27
                            [post_date_gmt] => 2020-05-21 20:22:27
                            [post_content] => 
                            [post_title] => Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-gilead-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 10:45:18
                            [post_modified_gmt] => 2022-09-27 10:45:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1083
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 11343
                            [post_author] => 5
                            [post_date] => 2023-10-10 08:51:06
                            [post_date_gmt] => 2023-10-10 08:51:06
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:25:05
                            [post_modified_gmt] => 2023-10-11 15:25:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11343
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 1103
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:41:55
                            [post_date_gmt] => 2020-05-21 20:41:55
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => merck-bsc-license-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:18:56
                            [post_modified_gmt] => 2022-10-11 12:18:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1103
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 3888
                            [post_author] => 5
                            [post_date] => 2021-11-19 12:49:16
                            [post_date_gmt] => 2021-11-19 12:49:16
                            [post_content] => 
                            [post_title] => Merck - MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:54:27
                            [post_modified_gmt] => 2023-01-27 14:54:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3888
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 1085
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:24:59
                            [post_date_gmt] => 2020-05-21 20:24:59
                            [post_content] => 
                            [post_title] => Merck - MPP, Raltegravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-merck-license-agreement-raltegravir
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:01:25
                            [post_modified_gmt] => 2023-09-18 12:01:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1085
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 3404
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:18:57
                            [post_date_gmt] => 2021-06-30 18:18:57
                            [post_content] => 
                            [post_title] => NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:02:05
                            [post_modified_gmt] => 2021-09-15 12:02:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3404
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 1092
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:32:35
                            [post_date_gmt] => 2020-05-21 20:32:35
                            [post_content] => 
                            [post_title] => NIH - Non-Profit, Model License Agreement Terms
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-model-license-agreement-for-use-by-non-profit
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:16:48
                            [post_modified_gmt] => 2021-09-15 12:16:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1092
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 11094
                            [post_author] => 5
                            [post_date] => 2023-08-31 08:20:34
                            [post_date_gmt] => 2023-08-31 08:20:34
                            [post_content] => 
                            [post_title] => NIH - UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-31 08:20:34
                            [post_modified_gmt] => 2023-08-31 08:20:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11094
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 5110
                            [post_author] => 5
                            [post_date] => 2022-06-29 11:57:22
                            [post_date_gmt] => 2022-06-29 11:57:22
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:40
                            [post_modified_gmt] => 2023-09-18 11:58:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5110
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 3794
                            [post_author] => 5
                            [post_date] => 2021-09-10 08:02:49
                            [post_date_gmt] => 2021-09-10 08:02:49
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-02-20 13:22:55
                            [post_modified_gmt] => 2023-02-20 13:22:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3794
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 4026
                            [post_author] => 5
                            [post_date] => 2021-12-21 11:36:17
                            [post_date_gmt] => 2021-12-21 11:36:17
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:21:01
                            [post_modified_gmt] => 2022-10-11 12:21:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4026
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 1091
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:31:42
                            [post_date_gmt] => 2020-05-21 20:31:42
                            [post_content] => 
                            [post_title] => Pfizer - MPP, Sutezolid License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-pfizer-license-agreement-sutezolid
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:01:38
                            [post_modified_gmt] => 2023-09-18 12:01:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1091
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 11063
                            [post_author] => 5
                            [post_date] => 2023-08-28 09:01:25
                            [post_date_gmt] => 2023-08-28 09:01:25
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 09:01:25
                            [post_modified_gmt] => 2023-08-28 09:01:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11063
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 11038
                            [post_author] => 5
                            [post_date] => 2023-08-24 10:34:46
                            [post_date_gmt] => 2023-08-24 10:34:46
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-biosyn-hiv-prophylactic-exclusive-licence-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 08:17:11
                            [post_modified_gmt] => 2023-08-28 08:17:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11038
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 11099
                            [post_author] => 5
                            [post_date] => 2023-08-31 10:33:35
                            [post_date_gmt] => 2023-08-31 10:33:35
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-31 10:33:35
                            [post_modified_gmt] => 2023-08-31 10:33:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11099
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 11079
                            [post_author] => 5
                            [post_date] => 2023-08-29 12:08:06
                            [post_date_gmt] => 2023-08-29 12:08:06
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 12:08:06
                            [post_modified_gmt] => 2023-08-29 12:08:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11079
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 2420
                            [post_author] => 5
                            [post_date] => 2020-12-14 14:59:07
                            [post_date_gmt] => 2020-12-14 14:59:07
                            [post_content] => 
                            [post_title] => Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => collaboration-and-license-agreement-between-sanofi-pasteur-inc-sanofi-and-translate-bio-ma-inc-translate-bio-or-tb-and-first-amendment-co
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:21:49
                            [post_modified_gmt] => 2022-10-11 12:21:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2420
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 5267
                            [post_author] => 5
                            [post_date] => 2022-07-07 13:47:03
                            [post_date_gmt] => 2022-07-07 13:47:03
                            [post_content] => 
                            [post_title] => Shionogi - GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:22:05
                            [post_modified_gmt] => 2022-10-11 12:22:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5267
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 11325
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:05:58
                            [post_date_gmt] => 2023-09-25 16:05:58
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-26 10:26:26
                            [post_modified_gmt] => 2023-09-26 10:26:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11325
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 1086
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:26:24
                            [post_date_gmt] => 2020-05-21 20:26:24
                            [post_content] => 
                            [post_title] => University of Liverpool - MPP, Solid Drug Nanoparticle Technology License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-univ-of-liverpool-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:01:51
                            [post_modified_gmt] => 2023-09-18 12:01:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1086
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 4070
                            [post_author] => 5
                            [post_date] => 2022-01-08 12:53:25
                            [post_date_gmt] => 2022-01-08 12:53:25
                            [post_content] => 
                            [post_title] => University of Washington - MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:02:20
                            [post_modified_gmt] => 2023-09-18 12:02:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4070
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 1089
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:30:11
                            [post_date_gmt] => 2020-05-21 20:30:11
                            [post_content] => 
                            [post_title] => ViiV - MPP, Dolutegravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-viiv-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:02:03
                            [post_modified_gmt] => 2023-09-18 12:02:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1089
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 38
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 1087
                    [post_author] => 6
                    [post_date] => 2020-05-21 20:27:18
                    [post_date_gmt] => 2020-05-21 20:27:18
                    [post_content] => 
                    [post_title] => AbbVie - MPP, HIV Antiretroviral License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-abbvie-license-agreement-lpv-r
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 11:59:26
                    [post_modified_gmt] => 2023-09-18 11:59:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=1087
                    [menu_order] => 0
                    [post_type] => agreement
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 38
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 1
            [is_search] => 
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => e64640c006c6ed735b67198eb04aaaca
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => 
            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                        )

                    [meta_query] => Array
                        (
                            [relation] => OR
                            [0] => Array
                                (
                                    [key] => agreement
                                    [value] => "1087"
                                    [compare] => LIKE
                                )

                            [1] => Array
                                (
                                    [key] => agreement
                                    [value] => "1084"
                                    [compare] => LIKE
                                )

                            [2] => Array
                                (
                                    [key] => agreement
                                    [value] => "9033"
                                    [compare] => LIKE
                                )

                            [3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1088"
                                    [compare] => LIKE
                                )

                            [4] => Array
                                (
                                    [key] => agreement
                                    [value] => "1090"
                                    [compare] => LIKE
                                )

                            [5] => Array
                                (
                                    [key] => agreement
                                    [value] => "1039"
                                    [compare] => LIKE
                                )

                            [6] => Array
                                (
                                    [key] => agreement
                                    [value] => "4467"
                                    [compare] => LIKE
                                )

                            [7] => Array
                                (
                                    [key] => agreement
                                    [value] => "4794"
                                    [compare] => LIKE
                                )

                            [8] => Array
                                (
                                    [key] => agreement
                                    [value] => "11245"
                                    [compare] => LIKE
                                )

                            [9] => Array
                                (
                                    [key] => agreement
                                    [value] => "3817"
                                    [compare] => LIKE
                                )

                            [10] => Array
                                (
                                    [key] => agreement
                                    [value] => "9858"
                                    [compare] => LIKE
                                )

                            [11] => Array
                                (
                                    [key] => agreement
                                    [value] => "9849"
                                    [compare] => LIKE
                                )

                            [12] => Array
                                (
                                    [key] => agreement
                                    [value] => "4832"
                                    [compare] => LIKE
                                )

                            [13] => Array
                                (
                                    [key] => agreement
                                    [value] => "11464"
                                    [compare] => LIKE
                                )

                            [14] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                )

                            [15] => Array
                                (
                                    [key] => agreement
                                    [value] => "1099"
                                    [compare] => LIKE
                                )

                            [16] => Array
                                (
                                    [key] => agreement
                                    [value] => "1083"
                                    [compare] => LIKE
                                )

                            [17] => Array
                                (
                                    [key] => agreement
                                    [value] => "11343"
                                    [compare] => LIKE
                                )

                            [18] => Array
                                (
                                    [key] => agreement
                                    [value] => "1103"
                                    [compare] => LIKE
                                )

                            [19] => Array
                                (
                                    [key] => agreement
                                    [value] => "3888"
                                    [compare] => LIKE
                                )

                            [20] => Array
                                (
                                    [key] => agreement
                                    [value] => "1085"
                                    [compare] => LIKE
                                )

                            [21] => Array
                                (
                                    [key] => agreement
                                    [value] => "3404"
                                    [compare] => LIKE
                                )

                            [22] => Array
                                (
                                    [key] => agreement
                                    [value] => "1092"
                                    [compare] => LIKE
                                )

                            [23] => Array
                                (
                                    [key] => agreement
                                    [value] => "11094"
                                    [compare] => LIKE
                                )

                            [24] => Array
                                (
                                    [key] => agreement
                                    [value] => "5110"
                                    [compare] => LIKE
                                )

                            [25] => Array
                                (
                                    [key] => agreement
                                    [value] => "3794"
                                    [compare] => LIKE
                                )

                            [26] => Array
                                (
                                    [key] => agreement
                                    [value] => "4026"
                                    [compare] => LIKE
                                )

                            [27] => Array
                                (
                                    [key] => agreement
                                    [value] => "1091"
                                    [compare] => LIKE
                                )

                            [28] => Array
                                (
                                    [key] => agreement
                                    [value] => "11063"
                                    [compare] => LIKE
                                )

                            [29] => Array
                                (
                                    [key] => agreement
                                    [value] => "11038"
                                    [compare] => LIKE
                                )

                            [30] => Array
                                (
                                    [key] => agreement
                                    [value] => "11099"
                                    [compare] => LIKE
                                )

                            [31] => Array
                                (
                                    [key] => agreement
                                    [value] => "11079"
                                    [compare] => LIKE
                                )

                            [32] => Array
                                (
                                    [key] => agreement
                                    [value] => "2420"
                                    [compare] => LIKE
                                )

                            [33] => Array
                                (
                                    [key] => agreement
                                    [value] => "5267"
                                    [compare] => LIKE
                                )

                            [34] => Array
                                (
                                    [key] => agreement
                                    [value] => "11325"
                                    [compare] => LIKE
                                )

                            [35] => Array
                                (
                                    [key] => agreement
                                    [value] => "1086"
                                    [compare] => LIKE
                                )

                            [36] => Array
                                (
                                    [key] => agreement
                                    [value] => "4070"
                                    [compare] => LIKE
                                )

                            [37] => Array
                                (
                                    [key] => agreement
                                    [value] => "1089"
                                    [compare] => LIKE
                                )

                        )

                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                        )

                    [meta_query] => Array
                        (
                            [relation] => OR
                            [0] => Array
                                (
                                    [key] => agreement
                                    [value] => "1087"
                                    [compare] => LIKE
                                )

                            [1] => Array
                                (
                                    [key] => agreement
                                    [value] => "1084"
                                    [compare] => LIKE
                                )

                            [2] => Array
                                (
                                    [key] => agreement
                                    [value] => "9033"
                                    [compare] => LIKE
                                )

                            [3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1088"
                                    [compare] => LIKE
                                )

                            [4] => Array
                                (
                                    [key] => agreement
                                    [value] => "1090"
                                    [compare] => LIKE
                                )

                            [5] => Array
                                (
                                    [key] => agreement
                                    [value] => "1039"
                                    [compare] => LIKE
                                )

                            [6] => Array
                                (
                                    [key] => agreement
                                    [value] => "4467"
                                    [compare] => LIKE
                                )

                            [7] => Array
                                (
                                    [key] => agreement
                                    [value] => "4794"
                                    [compare] => LIKE
                                )

                            [8] => Array
                                (
                                    [key] => agreement
                                    [value] => "11245"
                                    [compare] => LIKE
                                )

                            [9] => Array
                                (
                                    [key] => agreement
                                    [value] => "3817"
                                    [compare] => LIKE
                                )

                            [10] => Array
                                (
                                    [key] => agreement
                                    [value] => "9858"
                                    [compare] => LIKE
                                )

                            [11] => Array
                                (
                                    [key] => agreement
                                    [value] => "9849"
                                    [compare] => LIKE
                                )

                            [12] => Array
                                (
                                    [key] => agreement
                                    [value] => "4832"
                                    [compare] => LIKE
                                )

                            [13] => Array
                                (
                                    [key] => agreement
                                    [value] => "11464"
                                    [compare] => LIKE
                                )

                            [14] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                )

                            [15] => Array
                                (
                                    [key] => agreement
                                    [value] => "1099"
                                    [compare] => LIKE
                                )

                            [16] => Array
                                (
                                    [key] => agreement
                                    [value] => "1083"
                                    [compare] => LIKE
                                )

                            [17] => Array
                                (
                                    [key] => agreement
                                    [value] => "11343"
                                    [compare] => LIKE
                                )

                            [18] => Array
                                (
                                    [key] => agreement
                                    [value] => "1103"
                                    [compare] => LIKE
                                )

                            [19] => Array
                                (
                                    [key] => agreement
                                    [value] => "3888"
                                    [compare] => LIKE
                                )

                            [20] => Array
                                (
                                    [key] => agreement
                                    [value] => "1085"
                                    [compare] => LIKE
                                )

                            [21] => Array
                                (
                                    [key] => agreement
                                    [value] => "3404"
                                    [compare] => LIKE
                                )

                            [22] => Array
                                (
                                    [key] => agreement
                                    [value] => "1092"
                                    [compare] => LIKE
                                )

                            [23] => Array
                                (
                                    [key] => agreement
                                    [value] => "11094"
                                    [compare] => LIKE
                                )

                            [24] => Array
                                (
                                    [key] => agreement
                                    [value] => "5110"
                                    [compare] => LIKE
                                )

                            [25] => Array
                                (
                                    [key] => agreement
                                    [value] => "3794"
                                    [compare] => LIKE
                                )

                            [26] => Array
                                (
                                    [key] => agreement
                                    [value] => "4026"
                                    [compare] => LIKE
                                )

                            [27] => Array
                                (
                                    [key] => agreement
                                    [value] => "1091"
                                    [compare] => LIKE
                                )

                            [28] => Array
                                (
                                    [key] => agreement
                                    [value] => "11063"
                                    [compare] => LIKE
                                )

                            [29] => Array
                                (
                                    [key] => agreement
                                    [value] => "11038"
                                    [compare] => LIKE
                                )

                            [30] => Array
                                (
                                    [key] => agreement
                                    [value] => "11099"
                                    [compare] => LIKE
                                )

                            [31] => Array
                                (
                                    [key] => agreement
                                    [value] => "11079"
                                    [compare] => LIKE
                                )

                            [32] => Array
                                (
                                    [key] => agreement
                                    [value] => "2420"
                                    [compare] => LIKE
                                )

                            [33] => Array
                                (
                                    [key] => agreement
                                    [value] => "5267"
                                    [compare] => LIKE
                                )

                            [34] => Array
                                (
                                    [key] => agreement
                                    [value] => "11325"
                                    [compare] => LIKE
                                )

                            [35] => Array
                                (
                                    [key] => agreement
                                    [value] => "1086"
                                    [compare] => LIKE
                                )

                            [36] => Array
                                (
                                    [key] => agreement
                                    [value] => "4070"
                                    [compare] => LIKE
                                )

                            [37] => Array
                                (
                                    [key] => agreement
                                    [value] => "1089"
                                    [compare] => LIKE
                                )

                        )

                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [ignore_sticky_posts] => 
                    [suppress_filters] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                            [0] => Array
                                (
                                    [key] => agreement
                                    [value] => "1087"
                                    [compare] => LIKE
                                )

                            [1] => Array
                                (
                                    [key] => agreement
                                    [value] => "1084"
                                    [compare] => LIKE
                                )

                            [2] => Array
                                (
                                    [key] => agreement
                                    [value] => "9033"
                                    [compare] => LIKE
                                )

                            [3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1088"
                                    [compare] => LIKE
                                )

                            [4] => Array
                                (
                                    [key] => agreement
                                    [value] => "1090"
                                    [compare] => LIKE
                                )

                            [5] => Array
                                (
                                    [key] => agreement
                                    [value] => "1039"
                                    [compare] => LIKE
                                )

                            [6] => Array
                                (
                                    [key] => agreement
                                    [value] => "4467"
                                    [compare] => LIKE
                                )

                            [7] => Array
                                (
                                    [key] => agreement
                                    [value] => "4794"
                                    [compare] => LIKE
                                )

                            [8] => Array
                                (
                                    [key] => agreement
                                    [value] => "11245"
                                    [compare] => LIKE
                                )

                            [9] => Array
                                (
                                    [key] => agreement
                                    [value] => "3817"
                                    [compare] => LIKE
                                )

                            [10] => Array
                                (
                                    [key] => agreement
                                    [value] => "9858"
                                    [compare] => LIKE
                                )

                            [11] => Array
                                (
                                    [key] => agreement
                                    [value] => "9849"
                                    [compare] => LIKE
                                )

                            [12] => Array
                                (
                                    [key] => agreement
                                    [value] => "4832"
                                    [compare] => LIKE
                                )

                            [13] => Array
                                (
                                    [key] => agreement
                                    [value] => "11464"
                                    [compare] => LIKE
                                )

                            [14] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                )

                            [15] => Array
                                (
                                    [key] => agreement
                                    [value] => "1099"
                                    [compare] => LIKE
                                )

                            [16] => Array
                                (
                                    [key] => agreement
                                    [value] => "1083"
                                    [compare] => LIKE
                                )

                            [17] => Array
                                (
                                    [key] => agreement
                                    [value] => "11343"
                                    [compare] => LIKE
                                )

                            [18] => Array
                                (
                                    [key] => agreement
                                    [value] => "1103"
                                    [compare] => LIKE
                                )

                            [19] => Array
                                (
                                    [key] => agreement
                                    [value] => "3888"
                                    [compare] => LIKE
                                )

                            [20] => Array
                                (
                                    [key] => agreement
                                    [value] => "1085"
                                    [compare] => LIKE
                                )

                            [21] => Array
                                (
                                    [key] => agreement
                                    [value] => "3404"
                                    [compare] => LIKE
                                )

                            [22] => Array
                                (
                                    [key] => agreement
                                    [value] => "1092"
                                    [compare] => LIKE
                                )

                            [23] => Array
                                (
                                    [key] => agreement
                                    [value] => "11094"
                                    [compare] => LIKE
                                )

                            [24] => Array
                                (
                                    [key] => agreement
                                    [value] => "5110"
                                    [compare] => LIKE
                                )

                            [25] => Array
                                (
                                    [key] => agreement
                                    [value] => "3794"
                                    [compare] => LIKE
                                )

                            [26] => Array
                                (
                                    [key] => agreement
                                    [value] => "4026"
                                    [compare] => LIKE
                                )

                            [27] => Array
                                (
                                    [key] => agreement
                                    [value] => "1091"
                                    [compare] => LIKE
                                )

                            [28] => Array
                                (
                                    [key] => agreement
                                    [value] => "11063"
                                    [compare] => LIKE
                                )

                            [29] => Array
                                (
                                    [key] => agreement
                                    [value] => "11038"
                                    [compare] => LIKE
                                )

                            [30] => Array
                                (
                                    [key] => agreement
                                    [value] => "11099"
                                    [compare] => LIKE
                                )

                            [31] => Array
                                (
                                    [key] => agreement
                                    [value] => "11079"
                                    [compare] => LIKE
                                )

                            [32] => Array
                                (
                                    [key] => agreement
                                    [value] => "2420"
                                    [compare] => LIKE
                                )

                            [33] => Array
                                (
                                    [key] => agreement
                                    [value] => "5267"
                                    [compare] => LIKE
                                )

                            [34] => Array
                                (
                                    [key] => agreement
                                    [value] => "11325"
                                    [compare] => LIKE
                                )

                            [35] => Array
                                (
                                    [key] => agreement
                                    [value] => "1086"
                                    [compare] => LIKE
                                )

                            [36] => Array
                                (
                                    [key] => agreement
                                    [value] => "4070"
                                    [compare] => LIKE
                                )

                            [37] => Array
                                (
                                    [key] => agreement
                                    [value] => "1089"
                                    [compare] => LIKE
                                )

                            [relation] => OR
                        )

                    [relation] => OR
                    [meta_table] => wpry_postmeta
                    [meta_id_column] => post_id
                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                    [table_aliases:protected] => Array
                        (
                            [0] => wpry_postmeta
                        )

                    [clauses:protected] => Array
                        (
                            [wpry_postmeta] => Array
                                (
                                    [key] => agreement
                                    [value] => "1087"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-1] => Array
                                (
                                    [key] => agreement
                                    [value] => "1084"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-2] => Array
                                (
                                    [key] => agreement
                                    [value] => "9033"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-3] => Array
                                (
                                    [key] => agreement
                                    [value] => "1088"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-4] => Array
                                (
                                    [key] => agreement
                                    [value] => "1090"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-5] => Array
                                (
                                    [key] => agreement
                                    [value] => "1039"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-6] => Array
                                (
                                    [key] => agreement
                                    [value] => "4467"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-7] => Array
                                (
                                    [key] => agreement
                                    [value] => "4794"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-8] => Array
                                (
                                    [key] => agreement
                                    [value] => "11245"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-9] => Array
                                (
                                    [key] => agreement
                                    [value] => "3817"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-10] => Array
                                (
                                    [key] => agreement
                                    [value] => "9858"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-11] => Array
                                (
                                    [key] => agreement
                                    [value] => "9849"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-12] => Array
                                (
                                    [key] => agreement
                                    [value] => "4832"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-13] => Array
                                (
                                    [key] => agreement
                                    [value] => "11464"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-14] => Array
                                (
                                    [key] => agreement
                                    [value] => "3373"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-15] => Array
                                (
                                    [key] => agreement
                                    [value] => "1099"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-16] => Array
                                (
                                    [key] => agreement
                                    [value] => "1083"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-17] => Array
                                (
                                    [key] => agreement
                                    [value] => "11343"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-18] => Array
                                (
                                    [key] => agreement
                                    [value] => "1103"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-19] => Array
                                (
                                    [key] => agreement
                                    [value] => "3888"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-20] => Array
                                (
                                    [key] => agreement
                                    [value] => "1085"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-21] => Array
                                (
                                    [key] => agreement
                                    [value] => "3404"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-22] => Array
                                (
                                    [key] => agreement
                                    [value] => "1092"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-23] => Array
                                (
                                    [key] => agreement
                                    [value] => "11094"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-24] => Array
                                (
                                    [key] => agreement
                                    [value] => "5110"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-25] => Array
                                (
                                    [key] => agreement
                                    [value] => "3794"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-26] => Array
                                (
                                    [key] => agreement
                                    [value] => "4026"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-27] => Array
                                (
                                    [key] => agreement
                                    [value] => "1091"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-28] => Array
                                (
                                    [key] => agreement
                                    [value] => "11063"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-29] => Array
                                (
                                    [key] => agreement
                                    [value] => "11038"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-30] => Array
                                (
                                    [key] => agreement
                                    [value] => "11099"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-31] => Array
                                (
                                    [key] => agreement
                                    [value] => "11079"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-32] => Array
                                (
                                    [key] => agreement
                                    [value] => "2420"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-33] => Array
                                (
                                    [key] => agreement
                                    [value] => "5267"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-34] => Array
                                (
                                    [key] => agreement
                                    [value] => "11325"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-35] => Array
                                (
                                    [key] => agreement
                                    [value] => "1086"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-36] => Array
                                (
                                    [key] => agreement
                                    [value] => "4070"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                            [wpry_postmeta-37] => Array
                                (
                                    [key] => agreement
                                    [value] => "1089"
                                    [compare] => LIKE
                                    [compare_key] => =
                                    [alias] => wpry_postmeta
                                    [cast] => CHAR
                                )

                        )

                    [has_or_relation:protected] => 1
                )

            [date_query] => 
            [request] => 
			SELECT   wpry_posts.*
			FROM wpry_posts  INNER JOIN wpry_postmeta ON ( wpry_posts.ID = wpry_postmeta.post_id )
			WHERE 1=1  AND ( 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1087\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1084\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"9033\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1088\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1090\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1039\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"4467\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"4794\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"11245\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"3817\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"9858\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"9849\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"4832\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"11464\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"3373\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1099\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1083\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"11343\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1103\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"3888\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1085\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"3404\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1092\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"11094\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"5110\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"3794\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"4026\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1091\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"11063\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"11038\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"11099\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"11079\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"2420\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"5267\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"11325\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1086\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"4070\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' ) 
  OR 
  ( wpry_postmeta.meta_key = 'agreement' AND wpry_postmeta.meta_value LIKE '{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}\"1089\"{f0ae30b51f5d2fe0eeaa160d45c18d397b97d8ed87e165c0e99532ce8f8ae5f3}' )
) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
			GROUP BY wpry_posts.ID
			ORDER BY wpry_posts.post_date DESC
			
		
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 11483
                            [post_author] => 5
                            [post_date] => 2023-11-20 09:38:10
                            [post_date_gmt] => 2023-11-20 09:38:10
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:40:42
                            [post_modified_gmt] => 2023-11-20 09:40:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11483
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 11482
                            [post_author] => 5
                            [post_date] => 2023-11-20 09:34:04
                            [post_date_gmt] => 2023-11-20 09:34:04
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:34:04
                            [post_modified_gmt] => 2023-11-20 09:34:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 11481
                            [post_author] => 5
                            [post_date] => 2023-11-20 09:32:40
                            [post_date_gmt] => 2023-11-20 09:32:40
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:32:40
                            [post_modified_gmt] => 2023-11-20 09:32:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 11480
                            [post_author] => 5
                            [post_date] => 2023-11-20 09:24:22
                            [post_date_gmt] => 2023-11-20 09:24:22
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:31:52
                            [post_modified_gmt] => 2023-11-20 09:31:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11480
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 11479
                            [post_author] => 5
                            [post_date] => 2023-11-20 09:20:32
                            [post_date_gmt] => 2023-11-20 09:20:32
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:20:32
                            [post_modified_gmt] => 2023-11-20 09:20:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 11478
                            [post_author] => 5
                            [post_date] => 2023-11-20 09:18:25
                            [post_date_gmt] => 2023-11-20 09:18:25
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:18:25
                            [post_modified_gmt] => 2023-11-20 09:18:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11478
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 11477
                            [post_author] => 5
                            [post_date] => 2023-11-20 09:10:11
                            [post_date_gmt] => 2023-11-20 09:10:11
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:19:50
                            [post_modified_gmt] => 2023-11-20 09:19:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11477
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 11476
                            [post_author] => 5
                            [post_date] => 2023-11-20 08:57:12
                            [post_date_gmt] => 2023-11-20 08:57:12
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:18:05
                            [post_modified_gmt] => 2023-11-20 09:18:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11476
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 11474
                            [post_author] => 5
                            [post_date] => 2023-11-20 08:54:04
                            [post_date_gmt] => 2023-11-20 08:54:04
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 08:54:04
                            [post_modified_gmt] => 2023-11-20 08:54:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11474
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 11473
                            [post_author] => 5
                            [post_date] => 2023-11-20 08:50:29
                            [post_date_gmt] => 2023-11-20 08:50:29
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 08:51:41
                            [post_modified_gmt] => 2023-11-20 08:51:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11473
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 11472
                            [post_author] => 5
                            [post_date] => 2023-11-20 08:48:59
                            [post_date_gmt] => 2023-11-20 08:48:59
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:01:24
                            [post_modified_gmt] => 2023-11-20 09:01:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11472
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 11467
                            [post_author] => 5
                            [post_date] => 2023-11-20 08:46:09
                            [post_date_gmt] => 2023-11-20 08:46:09
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 08:46:09
                            [post_modified_gmt] => 2023-11-20 08:46:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 11471
                            [post_author] => 5
                            [post_date] => 2023-11-20 08:40:37
                            [post_date_gmt] => 2023-11-20 08:40:37
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 08:41:18
                            [post_modified_gmt] => 2023-11-20 08:41:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11471
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 11470
                            [post_author] => 5
                            [post_date] => 2023-11-20 08:39:41
                            [post_date_gmt] => 2023-11-20 08:39:41
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 08:39:41
                            [post_modified_gmt] => 2023-11-20 08:39:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11470
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 11468
                            [post_author] => 5
                            [post_date] => 2023-11-20 08:37:54
                            [post_date_gmt] => 2023-11-20 08:37:54
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:25:50
                            [post_modified_gmt] => 2023-11-20 09:25:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11468
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 11485
                            [post_author] => 5
                            [post_date] => 2023-11-20 08:32:36
                            [post_date_gmt] => 2023-11-20 08:32:36
                            [post_content] => 
                            [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 09:40:15
                            [post_modified_gmt] => 2023-11-20 09:40:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11485
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 11361
                            [post_author] => 5
                            [post_date] => 2023-10-11 15:17:51
                            [post_date_gmt] => 2023-10-11 15:17:51
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 16:01:11
                            [post_modified_gmt] => 2023-10-11 16:01:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11361
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 11360
                            [post_author] => 5
                            [post_date] => 2023-10-11 15:03:54
                            [post_date_gmt] => 2023-10-11 15:03:54
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 16:02:40
                            [post_modified_gmt] => 2023-10-11 16:02:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11360
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 11359
                            [post_author] => 5
                            [post_date] => 2023-10-11 14:14:13
                            [post_date_gmt] => 2023-10-11 14:14:13
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 16:00:13
                            [post_modified_gmt] => 2023-10-11 16:00:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11359
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 11358
                            [post_author] => 5
                            [post_date] => 2023-10-11 13:57:27
                            [post_date_gmt] => 2023-10-11 13:57:27
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:59:35
                            [post_modified_gmt] => 2023-10-11 15:59:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11358
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 11357
                            [post_author] => 5
                            [post_date] => 2023-10-11 13:42:17
                            [post_date_gmt] => 2023-10-11 13:42:17
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:59:14
                            [post_modified_gmt] => 2023-10-11 15:59:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11357
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 11356
                            [post_author] => 5
                            [post_date] => 2023-10-11 13:32:54
                            [post_date_gmt] => 2023-10-11 13:32:54
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:51:52
                            [post_modified_gmt] => 2023-10-11 15:51:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11356
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 11354
                            [post_author] => 5
                            [post_date] => 2023-10-11 12:48:35
                            [post_date_gmt] => 2023-10-11 12:48:35
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:52:44
                            [post_modified_gmt] => 2023-10-11 15:52:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11354
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 11353
                            [post_author] => 5
                            [post_date] => 2023-10-11 12:44:32
                            [post_date_gmt] => 2023-10-11 12:44:32
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:53:24
                            [post_modified_gmt] => 2023-10-11 15:53:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11353
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 11351
                            [post_author] => 5
                            [post_date] => 2023-10-11 12:30:03
                            [post_date_gmt] => 2023-10-11 12:30:03
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:56:38
                            [post_modified_gmt] => 2023-10-11 15:56:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11351
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 11350
                            [post_author] => 5
                            [post_date] => 2023-10-10 14:05:08
                            [post_date_gmt] => 2023-10-10 14:05:08
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:54:46
                            [post_modified_gmt] => 2023-10-11 15:54:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11350
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 11349
                            [post_author] => 5
                            [post_date] => 2023-10-10 13:26:39
                            [post_date_gmt] => 2023-10-10 13:26:39
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:54:08
                            [post_modified_gmt] => 2023-10-11 15:54:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11349
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 11347
                            [post_author] => 5
                            [post_date] => 2023-10-10 13:10:51
                            [post_date_gmt] => 2023-10-10 13:10:51
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:58:36
                            [post_modified_gmt] => 2023-10-11 15:58:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11347
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 11348
                            [post_author] => 5
                            [post_date] => 2023-10-10 12:20:52
                            [post_date_gmt] => 2023-10-10 12:20:52
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:52:12
                            [post_modified_gmt] => 2023-10-11 15:52:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11348
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 11346
                            [post_author] => 5
                            [post_date] => 2023-10-10 11:44:01
                            [post_date_gmt] => 2023-10-10 11:44:01
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:50:28
                            [post_modified_gmt] => 2023-10-11 15:50:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11346
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 11345
                            [post_author] => 5
                            [post_date] => 2023-10-10 09:45:26
                            [post_date_gmt] => 2023-10-10 09:45:26
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:57:28
                            [post_modified_gmt] => 2023-10-11 15:57:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11345
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 11337
                            [post_author] => 5
                            [post_date] => 2023-09-26 13:37:20
                            [post_date_gmt] => 2023-09-26 13:37:20
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:20:14
                            [post_modified_gmt] => 2023-09-27 09:20:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11337
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 11336
                            [post_author] => 5
                            [post_date] => 2023-09-26 12:26:24
                            [post_date_gmt] => 2023-09-26 12:26:24
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:19:55
                            [post_modified_gmt] => 2023-09-27 09:19:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11336
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 11335
                            [post_author] => 5
                            [post_date] => 2023-09-26 12:23:27
                            [post_date_gmt] => 2023-09-26 12:23:27
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:19:29
                            [post_modified_gmt] => 2023-09-27 09:19:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11335
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 11334
                            [post_author] => 5
                            [post_date] => 2023-09-26 12:20:43
                            [post_date_gmt] => 2023-09-26 12:20:43
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:17:25
                            [post_modified_gmt] => 2023-09-27 09:17:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11334
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 11333
                            [post_author] => 5
                            [post_date] => 2023-09-26 10:31:42
                            [post_date_gmt] => 2023-09-26 10:31:42
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:17:46
                            [post_modified_gmt] => 2023-09-27 09:17:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11333
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 11331
                            [post_author] => 5
                            [post_date] => 2023-09-26 10:25:29
                            [post_date_gmt] => 2023-09-26 10:25:29
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:18:47
                            [post_modified_gmt] => 2023-09-27 09:18:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11331
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 11330
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:33:25
                            [post_date_gmt] => 2023-09-25 16:33:25
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:18:26
                            [post_modified_gmt] => 2023-09-27 09:18:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11330
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 11329
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:31:48
                            [post_date_gmt] => 2023-09-25 16:31:48
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:18:04
                            [post_modified_gmt] => 2023-09-27 09:18:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11329
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 11328
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:22:13
                            [post_date_gmt] => 2023-09-25 16:22:13
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:16:55
                            [post_modified_gmt] => 2023-09-27 09:16:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11328
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 11327
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:20:19
                            [post_date_gmt] => 2023-09-25 16:20:19
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:19:08
                            [post_modified_gmt] => 2023-09-27 09:19:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11327
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 11260
                            [post_author] => 5
                            [post_date] => 2023-09-18 11:51:39
                            [post_date_gmt] => 2023-09-18 11:51:39
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:51:39
                            [post_modified_gmt] => 2023-09-18 11:51:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11260
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 11259
                            [post_author] => 5
                            [post_date] => 2023-09-18 11:17:07
                            [post_date_gmt] => 2023-09-18 11:17:07
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:17:07
                            [post_modified_gmt] => 2023-09-18 11:17:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11259
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 11258
                            [post_author] => 5
                            [post_date] => 2023-09-18 11:14:03
                            [post_date_gmt] => 2023-09-18 11:14:03
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:14:03
                            [post_modified_gmt] => 2023-09-18 11:14:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11258
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 11257
                            [post_author] => 5
                            [post_date] => 2023-09-18 10:52:07
                            [post_date_gmt] => 2023-09-18 10:52:07
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:52:21
                            [post_modified_gmt] => 2023-09-18 11:52:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11257
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [45] => WP_Post Object
                        (
                            [ID] => 11256
                            [post_author] => 5
                            [post_date] => 2023-09-18 10:42:58
                            [post_date_gmt] => 2023-09-18 10:42:58
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 10:42:58
                            [post_modified_gmt] => 2023-09-18 10:42:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11256
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [46] => WP_Post Object
                        (
                            [ID] => 11255
                            [post_author] => 5
                            [post_date] => 2023-09-18 10:36:46
                            [post_date_gmt] => 2023-09-18 10:36:46
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 10:37:13
                            [post_modified_gmt] => 2023-09-18 10:37:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11255
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [47] => WP_Post Object
                        (
                            [ID] => 11254
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:49:03
                            [post_date_gmt] => 2023-09-18 09:49:03
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:49:03
                            [post_modified_gmt] => 2023-09-18 09:49:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11254
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [48] => WP_Post Object
                        (
                            [ID] => 11252
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:45:34
                            [post_date_gmt] => 2023-09-18 09:45:34
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:45:34
                            [post_modified_gmt] => 2023-09-18 09:45:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11252
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [49] => WP_Post Object
                        (
                            [ID] => 11251
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:38:14
                            [post_date_gmt] => 2023-09-18 09:38:14
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:38:14
                            [post_modified_gmt] => 2023-09-18 09:38:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11251
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [50] => WP_Post Object
                        (
                            [ID] => 11250
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:35:19
                            [post_date_gmt] => 2023-09-18 09:35:19
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:35:19
                            [post_modified_gmt] => 2023-09-18 09:35:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11250
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [51] => WP_Post Object
                        (
                            [ID] => 11248
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:31:07
                            [post_date_gmt] => 2023-09-18 09:31:07
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:31:07
                            [post_modified_gmt] => 2023-09-18 09:31:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11248
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [52] => WP_Post Object
                        (
                            [ID] => 11247
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:17:13
                            [post_date_gmt] => 2023-09-18 09:17:13
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:32:09
                            [post_modified_gmt] => 2023-09-18 09:32:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11247
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [53] => WP_Post Object
                        (
                            [ID] => 11134
                            [post_author] => 5
                            [post_date] => 2023-09-04 13:43:48
                            [post_date_gmt] => 2023-09-04 13:43:48
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:43:48
                            [post_modified_gmt] => 2023-09-04 13:43:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11134
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [54] => WP_Post Object
                        (
                            [ID] => 11133
                            [post_author] => 5
                            [post_date] => 2023-09-04 13:30:07
                            [post_date_gmt] => 2023-09-04 13:30:07
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:44:48
                            [post_modified_gmt] => 2023-09-04 13:44:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11133
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [55] => WP_Post Object
                        (
                            [ID] => 11132
                            [post_author] => 5
                            [post_date] => 2023-09-04 13:10:26
                            [post_date_gmt] => 2023-09-04 13:10:26
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:10:26
                            [post_modified_gmt] => 2023-09-04 13:10:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11132
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [56] => WP_Post Object
                        (
                            [ID] => 11131
                            [post_author] => 5
                            [post_date] => 2023-09-04 13:07:25
                            [post_date_gmt] => 2023-09-04 13:07:25
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:07:25
                            [post_modified_gmt] => 2023-09-04 13:07:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [57] => WP_Post Object
                        (
                            [ID] => 11130
                            [post_author] => 5
                            [post_date] => 2023-09-04 13:04:47
                            [post_date_gmt] => 2023-09-04 13:04:47
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:04:47
                            [post_modified_gmt] => 2023-09-04 13:04:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [58] => WP_Post Object
                        (
                            [ID] => 11129
                            [post_author] => 5
                            [post_date] => 2023-09-04 12:53:59
                            [post_date_gmt] => 2023-09-04 12:53:59
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:42:57
                            [post_modified_gmt] => 2023-11-10 14:42:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [59] => WP_Post Object
                        (
                            [ID] => 11128
                            [post_author] => 5
                            [post_date] => 2023-09-04 12:35:39
                            [post_date_gmt] => 2023-09-04 12:35:39
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 12:36:50
                            [post_modified_gmt] => 2023-09-04 12:36:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11128
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [60] => WP_Post Object
                        (
                            [ID] => 11127
                            [post_author] => 5
                            [post_date] => 2023-09-04 12:07:04
                            [post_date_gmt] => 2023-09-04 12:07:04
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 12:22:43
                            [post_modified_gmt] => 2023-09-04 12:22:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11127
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [61] => WP_Post Object
                        (
                            [ID] => 11126
                            [post_author] => 5
                            [post_date] => 2023-09-04 11:45:05
                            [post_date_gmt] => 2023-09-04 11:45:05
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:40:47
                            [post_modified_gmt] => 2023-09-04 13:40:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11126
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [62] => WP_Post Object
                        (
                            [ID] => 11125
                            [post_author] => 5
                            [post_date] => 2023-09-04 11:24:43
                            [post_date_gmt] => 2023-09-04 11:24:43
                            [post_content] => 
                            [post_title] => NIH - UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:38:26
                            [post_modified_gmt] => 2023-09-04 13:38:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11125
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [63] => WP_Post Object
                        (
                            [ID] => 11124
                            [post_author] => 5
                            [post_date] => 2023-09-04 10:26:26
                            [post_date_gmt] => 2023-09-04 10:26:26
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 10:26:26
                            [post_modified_gmt] => 2023-09-04 10:26:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11124
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [64] => WP_Post Object
                        (
                            [ID] => 11123
                            [post_author] => 5
                            [post_date] => 2023-09-04 10:23:35
                            [post_date_gmt] => 2023-09-04 10:23:35
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:45:31
                            [post_modified_gmt] => 2023-09-04 13:45:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [65] => WP_Post Object
                        (
                            [ID] => 11118
                            [post_author] => 5
                            [post_date] => 2023-09-04 09:54:48
                            [post_date_gmt] => 2023-09-04 09:54:48
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 09:55:20
                            [post_modified_gmt] => 2023-09-04 09:55:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11118
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [66] => WP_Post Object
                        (
                            [ID] => 11116
                            [post_author] => 5
                            [post_date] => 2023-09-01 12:33:27
                            [post_date_gmt] => 2023-09-01 12:33:27
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-20 12:51:48
                            [post_modified_gmt] => 2023-11-20 12:51:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11116
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [67] => WP_Post Object
                        (
                            [ID] => 11114
                            [post_author] => 5
                            [post_date] => 2023-09-01 12:30:00
                            [post_date_gmt] => 2023-09-01 12:30:00
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-01 12:41:24
                            [post_modified_gmt] => 2023-09-01 12:41:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11114
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [68] => WP_Post Object
                        (
                            [ID] => 11113
                            [post_author] => 5
                            [post_date] => 2023-09-01 12:26:23
                            [post_date_gmt] => 2023-09-01 12:26:23
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:58:18
                            [post_modified_gmt] => 2023-11-10 14:58:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11113
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [69] => WP_Post Object
                        (
                            [ID] => 11107
                            [post_author] => 5
                            [post_date] => 2023-08-31 14:53:13
                            [post_date_gmt] => 2023-08-31 14:53:13
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 12:08:07
                            [post_modified_gmt] => 2023-09-04 12:08:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11107
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [70] => WP_Post Object
                        (
                            [ID] => 11106
                            [post_author] => 5
                            [post_date] => 2023-08-31 12:52:01
                            [post_date_gmt] => 2023-08-31 12:52:01
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-01 12:42:49
                            [post_modified_gmt] => 2023-09-01 12:42:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11106
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [71] => WP_Post Object
                        (
                            [ID] => 11105
                            [post_author] => 5
                            [post_date] => 2023-08-31 12:50:06
                            [post_date_gmt] => 2023-08-31 12:50:06
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-01 12:43:07
                            [post_modified_gmt] => 2023-09-01 12:43:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11105
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [72] => WP_Post Object
                        (
                            [ID] => 11104
                            [post_author] => 5
                            [post_date] => 2023-08-31 11:48:00
                            [post_date_gmt] => 2023-08-31 11:48:00
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-01 12:43:25
                            [post_modified_gmt] => 2023-09-01 12:43:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11104
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [73] => WP_Post Object
                        (
                            [ID] => 11103
                            [post_author] => 5
                            [post_date] => 2023-08-31 11:41:15
                            [post_date_gmt] => 2023-08-31 11:41:15
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-01 12:45:05
                            [post_modified_gmt] => 2023-09-01 12:45:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11103
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [74] => WP_Post Object
                        (
                            [ID] => 11102
                            [post_author] => 5
                            [post_date] => 2023-08-31 11:25:29
                            [post_date_gmt] => 2023-08-31 11:25:29
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-01 12:45:30
                            [post_modified_gmt] => 2023-09-01 12:45:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11102
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [75] => WP_Post Object
                        (
                            [ID] => 11101
                            [post_author] => 5
                            [post_date] => 2023-08-31 11:04:44
                            [post_date_gmt] => 2023-08-31 11:04:44
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-01 12:45:47
                            [post_modified_gmt] => 2023-09-01 12:45:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11101
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [76] => WP_Post Object
                        (
                            [ID] => 11097
                            [post_author] => 5
                            [post_date] => 2023-08-31 10:10:17
                            [post_date_gmt] => 2023-08-31 10:10:17
                            [post_content] => 
                            [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 12:21:34
                            [post_modified_gmt] => 2023-09-04 12:21:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11097
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [77] => WP_Post Object
                        (
                            [ID] => 11096
                            [post_author] => 5
                            [post_date] => 2023-08-31 09:33:42
                            [post_date_gmt] => 2023-08-31 09:33:42
                            [post_content] => 
                            [post_title] => NIH - UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-31 10:11:08
                            [post_modified_gmt] => 2023-08-31 10:11:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11096
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [78] => WP_Post Object
                        (
                            [ID] => 11093
                            [post_author] => 5
                            [post_date] => 2023-08-30 15:21:05
                            [post_date_gmt] => 2023-08-30 15:21:05
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-30 15:21:05
                            [post_modified_gmt] => 2023-08-30 15:21:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11093
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [79] => WP_Post Object
                        (
                            [ID] => 11092
                            [post_author] => 5
                            [post_date] => 2023-08-30 15:15:53
                            [post_date_gmt] => 2023-08-30 15:15:53
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:46:13
                            [post_modified_gmt] => 2023-09-04 13:46:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11092
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [80] => WP_Post Object
                        (
                            [ID] => 11091
                            [post_author] => 5
                            [post_date] => 2023-08-30 14:56:10
                            [post_date_gmt] => 2023-08-30 14:56:10
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 09:55:32
                            [post_modified_gmt] => 2023-09-04 09:55:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11091
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [81] => WP_Post Object
                        (
                            [ID] => 11090
                            [post_author] => 5
                            [post_date] => 2023-08-30 14:52:31
                            [post_date_gmt] => 2023-08-30 14:52:31
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-30 14:52:31
                            [post_modified_gmt] => 2023-08-30 14:52:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11090
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [82] => WP_Post Object
                        (
                            [ID] => 11089
                            [post_author] => 5
                            [post_date] => 2023-08-30 14:38:46
                            [post_date_gmt] => 2023-08-30 14:38:46
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-30 14:38:46
                            [post_modified_gmt] => 2023-08-30 14:38:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11089
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [83] => WP_Post Object
                        (
                            [ID] => 11088
                            [post_author] => 5
                            [post_date] => 2023-08-30 14:31:40
                            [post_date_gmt] => 2023-08-30 14:31:40
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:58:36
                            [post_modified_gmt] => 2023-11-10 14:58:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11088
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [84] => WP_Post Object
                        (
                            [ID] => 11087
                            [post_author] => 5
                            [post_date] => 2023-08-29 15:34:57
                            [post_date_gmt] => 2023-08-29 15:34:57
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 11087
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 12:07:36
                            [post_modified_gmt] => 2023-09-04 12:07:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11087
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [85] => WP_Post Object
                        (
                            [ID] => 11086
                            [post_author] => 5
                            [post_date] => 2023-08-29 14:25:37
                            [post_date_gmt] => 2023-08-29 14:25:37
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-31 12:57:48
                            [post_modified_gmt] => 2023-08-31 12:57:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11086
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [86] => WP_Post Object
                        (
                            [ID] => 11085
                            [post_author] => 5
                            [post_date] => 2023-08-29 13:58:20
                            [post_date_gmt] => 2023-08-29 13:58:20
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 13:58:20
                            [post_modified_gmt] => 2023-08-29 13:58:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11085
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [87] => WP_Post Object
                        (
                            [ID] => 11084
                            [post_author] => 5
                            [post_date] => 2023-08-29 13:34:09
                            [post_date_gmt] => 2023-08-29 13:34:09
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 13:58:43
                            [post_modified_gmt] => 2023-08-29 13:58:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11084
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [88] => WP_Post Object
                        (
                            [ID] => 11083
                            [post_author] => 5
                            [post_date] => 2023-08-29 13:04:02
                            [post_date_gmt] => 2023-08-29 13:04:02
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 13:04:02
                            [post_modified_gmt] => 2023-08-29 13:04:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11083
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [89] => WP_Post Object
                        (
                            [ID] => 11082
                            [post_author] => 5
                            [post_date] => 2023-08-29 13:00:36
                            [post_date_gmt] => 2023-08-29 13:00:36
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 13:00:36
                            [post_modified_gmt] => 2023-08-29 13:00:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11082
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [90] => WP_Post Object
                        (
                            [ID] => 11081
                            [post_author] => 5
                            [post_date] => 2023-08-29 12:46:57
                            [post_date_gmt] => 2023-08-29 12:46:57
                            [post_content] => 
                            [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 12:46:57
                            [post_modified_gmt] => 2023-08-29 12:46:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11081
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [91] => WP_Post Object
                        (
                            [ID] => 11078
                            [post_author] => 5
                            [post_date] => 2023-08-29 08:34:35
                            [post_date_gmt] => 2023-08-29 08:34:35
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 08:34:35
                            [post_modified_gmt] => 2023-08-29 08:34:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11078
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [92] => WP_Post Object
                        (
                            [ID] => 11077
                            [post_author] => 5
                            [post_date] => 2023-08-29 08:31:51
                            [post_date_gmt] => 2023-08-29 08:31:51
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:52:03
                            [post_modified_gmt] => 2023-09-04 13:52:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11077
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [93] => WP_Post Object
                        (
                            [ID] => 11076
                            [post_author] => 5
                            [post_date] => 2023-08-29 07:51:48
                            [post_date_gmt] => 2023-08-29 07:51:48
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 07:51:48
                            [post_modified_gmt] => 2023-08-29 07:51:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11076
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [94] => WP_Post Object
                        (
                            [ID] => 11075
                            [post_author] => 5
                            [post_date] => 2023-08-29 07:22:26
                            [post_date_gmt] => 2023-08-29 07:22:26
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 07:23:23
                            [post_modified_gmt] => 2023-08-29 07:23:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11075
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [95] => WP_Post Object
                        (
                            [ID] => 11074
                            [post_author] => 5
                            [post_date] => 2023-08-29 07:10:44
                            [post_date_gmt] => 2023-08-29 07:10:44
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:57:50
                            [post_modified_gmt] => 2023-11-10 14:57:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11074
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [96] => WP_Post Object
                        (
                            [ID] => 11073
                            [post_author] => 5
                            [post_date] => 2023-08-28 17:57:35
                            [post_date_gmt] => 2023-08-28 17:57:35
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 17:58:29
                            [post_modified_gmt] => 2023-08-28 17:58:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11073
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [97] => WP_Post Object
                        (
                            [ID] => 11072
                            [post_author] => 5
                            [post_date] => 2023-08-28 17:50:37
                            [post_date_gmt] => 2023-08-28 17:50:37
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 17:50:37
                            [post_modified_gmt] => 2023-08-28 17:50:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11072
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [98] => WP_Post Object
                        (
                            [ID] => 11071
                            [post_author] => 5
                            [post_date] => 2023-08-28 12:56:19
                            [post_date_gmt] => 2023-08-28 12:56:19
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 13:22:48
                            [post_modified_gmt] => 2023-08-29 13:22:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11071
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [99] => WP_Post Object
                        (
                            [ID] => 11070
                            [post_author] => 5
                            [post_date] => 2023-08-28 12:29:24
                            [post_date_gmt] => 2023-08-28 12:29:24
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 12:29:24
                            [post_modified_gmt] => 2023-08-28 12:29:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11070
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [100] => WP_Post Object
                        (
                            [ID] => 11069
                            [post_author] => 5
                            [post_date] => 2023-08-28 12:24:54
                            [post_date_gmt] => 2023-08-28 12:24:54
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 12:24:54
                            [post_modified_gmt] => 2023-08-28 12:24:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11069
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [101] => WP_Post Object
                        (
                            [ID] => 11068
                            [post_author] => 5
                            [post_date] => 2023-08-28 11:48:12
                            [post_date_gmt] => 2023-08-28 11:48:12
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 08:36:23
                            [post_modified_gmt] => 2023-08-29 08:36:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11068
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [102] => WP_Post Object
                        (
                            [ID] => 11067
                            [post_author] => 5
                            [post_date] => 2023-08-28 11:10:31
                            [post_date_gmt] => 2023-08-28 11:10:31
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 08:38:45
                            [post_modified_gmt] => 2023-08-29 08:38:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11067
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [103] => WP_Post Object
                        (
                            [ID] => 11065
                            [post_author] => 5
                            [post_date] => 2023-08-28 10:57:09
                            [post_date_gmt] => 2023-08-28 10:57:09
                            [post_content] => 
                            [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:48:45
                            [post_modified_gmt] => 2023-09-04 13:48:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11065
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [104] => WP_Post Object
                        (
                            [ID] => 11062
                            [post_author] => 5
                            [post_date] => 2023-08-25 09:33:29
                            [post_date_gmt] => 2023-08-25 09:33:29
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 08:17:36
                            [post_modified_gmt] => 2023-08-28 08:17:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11062
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [105] => WP_Post Object
                        (
                            [ID] => 11045
                            [post_author] => 5
                            [post_date] => 2023-08-25 09:19:42
                            [post_date_gmt] => 2023-08-25 09:19:42
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:41:23
                            [post_modified_gmt] => 2023-11-10 14:41:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11045
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [106] => WP_Post Object
                        (
                            [ID] => 11053
                            [post_author] => 5
                            [post_date] => 2023-08-25 09:07:42
                            [post_date_gmt] => 2023-08-25 09:07:42
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 07:22:15
                            [post_modified_gmt] => 2023-08-29 07:22:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11053
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [107] => WP_Post Object
                        (
                            [ID] => 11061
                            [post_author] => 5
                            [post_date] => 2023-08-25 08:44:53
                            [post_date_gmt] => 2023-08-25 08:44:53
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 08:18:03
                            [post_modified_gmt] => 2023-08-28 08:18:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11061
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [108] => WP_Post Object
                        (
                            [ID] => 11057
                            [post_author] => 5
                            [post_date] => 2023-08-25 08:38:20
                            [post_date_gmt] => 2023-08-25 08:38:20
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 17:55:13
                            [post_modified_gmt] => 2023-08-28 17:55:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11057
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [109] => WP_Post Object
                        (
                            [ID] => 11059
                            [post_author] => 5
                            [post_date] => 2023-08-25 07:54:12
                            [post_date_gmt] => 2023-08-25 07:54:12
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 08:29:41
                            [post_modified_gmt] => 2023-08-29 08:29:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11059
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [110] => WP_Post Object
                        (
                            [ID] => 11060
                            [post_author] => 5
                            [post_date] => 2023-08-25 07:36:19
                            [post_date_gmt] => 2023-08-25 07:36:19
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 11:33:07
                            [post_modified_gmt] => 2023-08-28 11:33:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11060
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [111] => WP_Post Object
                        (
                            [ID] => 11058
                            [post_author] => 5
                            [post_date] => 2023-08-25 06:41:12
                            [post_date_gmt] => 2023-08-25 06:41:12
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 07:37:53
                            [post_modified_gmt] => 2023-08-29 07:37:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11058
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [112] => WP_Post Object
                        (
                            [ID] => 11044
                            [post_author] => 5
                            [post_date] => 2023-08-24 15:28:36
                            [post_date_gmt] => 2023-08-24 15:28:36
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 08:18:43
                            [post_modified_gmt] => 2023-08-28 08:18:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11044
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [113] => WP_Post Object
                        (
                            [ID] => 11056
                            [post_author] => 5
                            [post_date] => 2023-08-24 14:52:21
                            [post_date_gmt] => 2023-08-24 14:52:21
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 08:18:49
                            [post_modified_gmt] => 2023-08-28 08:18:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11056
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [114] => WP_Post Object
                        (
                            [ID] => 11055
                            [post_author] => 5
                            [post_date] => 2023-08-24 14:04:36
                            [post_date_gmt] => 2023-08-24 14:04:36
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 08:18:54
                            [post_modified_gmt] => 2023-08-28 08:18:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11055
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [115] => WP_Post Object
                        (
                            [ID] => 11054
                            [post_author] => 5
                            [post_date] => 2023-08-24 13:49:48
                            [post_date_gmt] => 2023-08-24 13:49:48
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 08:19:00
                            [post_modified_gmt] => 2023-08-28 08:19:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11054
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [116] => WP_Post Object
                        (
                            [ID] => 11040
                            [post_author] => 5
                            [post_date] => 2023-08-24 12:12:13
                            [post_date_gmt] => 2023-08-24 12:12:13
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 13:53:13
                            [post_modified_gmt] => 2023-09-04 13:53:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11040
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [117] => WP_Post Object
                        (
                            [ID] => 11043
                            [post_author] => 5
                            [post_date] => 2023-08-24 11:33:31
                            [post_date_gmt] => 2023-08-24 11:33:31
                            [post_content] => 
                            [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-28 08:19:12
                            [post_modified_gmt] => 2023-08-28 08:19:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11043
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [118] => WP_Post Object
                        (
                            [ID] => 11005
                            [post_author] => 5
                            [post_date] => 2023-08-11 14:24:06
                            [post_date_gmt] => 2023-08-11 14:24:06
                            [post_content] => 
                            [post_title] => NIH - Non-Profit, Model License Agreement Terms
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-non-profit-model-license-agreement-terms-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 14:24:06
                            [post_modified_gmt] => 2023-08-11 14:24:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11005
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [119] => WP_Post Object
                        (
                            [ID] => 11004
                            [post_author] => 5
                            [post_date] => 2023-08-11 14:17:46
                            [post_date_gmt] => 2023-08-11 14:17:46
                            [post_content] => 
                            [post_title] => NIH - Non-Profit, Model License Agreement Terms
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-non-profit-model-license-agreement-terms-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 14:17:46
                            [post_modified_gmt] => 2023-08-11 14:17:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11004
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [120] => WP_Post Object
                        (
                            [ID] => 11002
                            [post_author] => 5
                            [post_date] => 2023-08-11 14:04:44
                            [post_date_gmt] => 2023-08-11 14:04:44
                            [post_content] => 
                            [post_title] => NIH - Non-Profit, Model License Agreement Terms
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 11002
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 14:07:47
                            [post_modified_gmt] => 2023-08-11 14:07:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11002
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [121] => WP_Post Object
                        (
                            [ID] => 11000
                            [post_author] => 5
                            [post_date] => 2023-08-11 12:50:35
                            [post_date_gmt] => 2023-08-11 12:50:35
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-30 14:55:11
                            [post_modified_gmt] => 2023-08-30 14:55:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11000
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [122] => WP_Post Object
                        (
                            [ID] => 10999
                            [post_author] => 5
                            [post_date] => 2023-08-11 11:36:21
                            [post_date_gmt] => 2023-08-11 11:36:21
                            [post_content] => 
                            [post_title] => NIH - Non-Profit, Model License Agreement Terms
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-non-profit-model-license-agreement-terms
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 14:07:14
                            [post_modified_gmt] => 2023-08-11 14:07:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=10999
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [123] => WP_Post Object
                        (
                            [ID] => 9894
                            [post_author] => 5
                            [post_date] => 2023-04-20 12:27:42
                            [post_date_gmt] => 2023-04-20 12:27:42
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-05 15:00:14
                            [post_modified_gmt] => 2023-06-05 15:00:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9894
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [124] => WP_Post Object
                        (
                            [ID] => 9893
                            [post_author] => 5
                            [post_date] => 2023-04-20 12:20:05
                            [post_date_gmt] => 2023-04-20 12:20:05
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 11:43:45
                            [post_modified_gmt] => 2023-06-27 11:43:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9893
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [125] => WP_Post Object
                        (
                            [ID] => 9892
                            [post_author] => 5
                            [post_date] => 2023-04-20 12:00:13
                            [post_date_gmt] => 2023-04-20 12:00:13
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:38:43
                            [post_modified_gmt] => 2023-06-27 13:38:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [126] => WP_Post Object
                        (
                            [ID] => 9891
                            [post_author] => 5
                            [post_date] => 2023-04-20 08:44:23
                            [post_date_gmt] => 2023-04-20 08:44:23
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:41:12
                            [post_modified_gmt] => 2023-06-27 13:41:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9891
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [127] => WP_Post Object
                        (
                            [ID] => 9890
                            [post_author] => 5
                            [post_date] => 2023-04-20 08:28:58
                            [post_date_gmt] => 2023-04-20 08:28:58
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:39:29
                            [post_modified_gmt] => 2023-06-27 13:39:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9890
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [128] => WP_Post Object
                        (
                            [ID] => 9889
                            [post_author] => 5
                            [post_date] => 2023-04-20 08:26:21
                            [post_date_gmt] => 2023-04-20 08:26:21
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:27:42
                            [post_modified_gmt] => 2023-06-27 13:27:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9889
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [129] => WP_Post Object
                        (
                            [ID] => 9888
                            [post_author] => 5
                            [post_date] => 2023-04-20 08:15:26
                            [post_date_gmt] => 2023-04-20 08:15:26
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:20:51
                            [post_modified_gmt] => 2023-06-27 13:20:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9888
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [130] => WP_Post Object
                        (
                            [ID] => 9886
                            [post_author] => 5
                            [post_date] => 2023-04-20 08:00:35
                            [post_date_gmt] => 2023-04-20 08:00:35
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:15:10
                            [post_modified_gmt] => 2023-06-27 13:15:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9886
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [131] => WP_Post Object
                        (
                            [ID] => 9885
                            [post_author] => 5
                            [post_date] => 2023-04-19 15:03:20
                            [post_date_gmt] => 2023-04-19 15:03:20
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 08:20:27
                            [post_modified_gmt] => 2023-10-17 08:20:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9885
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [132] => WP_Post Object
                        (
                            [ID] => 9884
                            [post_author] => 5
                            [post_date] => 2023-04-19 14:28:15
                            [post_date_gmt] => 2023-04-19 14:28:15
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 08:21:50
                            [post_modified_gmt] => 2023-10-17 08:21:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9884
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [133] => WP_Post Object
                        (
                            [ID] => 9883
                            [post_author] => 5
                            [post_date] => 2023-04-19 13:59:07
                            [post_date_gmt] => 2023-04-19 13:59:07
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 08:19:57
                            [post_modified_gmt] => 2023-10-17 08:19:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9883
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [134] => WP_Post Object
                        (
                            [ID] => 9882
                            [post_author] => 5
                            [post_date] => 2023-04-19 13:38:50
                            [post_date_gmt] => 2023-04-19 13:38:50
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:12:35
                            [post_modified_gmt] => 2023-06-27 13:12:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9882
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [135] => WP_Post Object
                        (
                            [ID] => 9881
                            [post_author] => 5
                            [post_date] => 2023-04-19 13:28:03
                            [post_date_gmt] => 2023-04-19 13:28:03
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:29:59
                            [post_modified_gmt] => 2023-06-27 13:29:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9881
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [136] => WP_Post Object
                        (
                            [ID] => 9880
                            [post_author] => 5
                            [post_date] => 2023-04-19 13:15:50
                            [post_date_gmt] => 2023-04-19 13:15:50
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 11:54:53
                            [post_modified_gmt] => 2023-06-27 11:54:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9880
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [137] => WP_Post Object
                        (
                            [ID] => 9879
                            [post_author] => 5
                            [post_date] => 2023-04-19 13:00:06
                            [post_date_gmt] => 2023-04-19 13:00:06
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-13 12:28:59
                            [post_modified_gmt] => 2023-07-13 12:28:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9879
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [138] => WP_Post Object
                        (
                            [ID] => 9877
                            [post_author] => 5
                            [post_date] => 2023-04-19 11:54:25
                            [post_date_gmt] => 2023-04-19 11:54:25
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:12:20
                            [post_modified_gmt] => 2023-11-10 14:12:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9877
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [139] => WP_Post Object
                        (
                            [ID] => 9875
                            [post_author] => 5
                            [post_date] => 2023-04-19 10:41:01
                            [post_date_gmt] => 2023-04-19 10:41:01
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 11:59:40
                            [post_modified_gmt] => 2023-06-27 11:59:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9875
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [140] => WP_Post Object
                        (
                            [ID] => 9874
                            [post_author] => 5
                            [post_date] => 2023-04-18 15:17:41
                            [post_date_gmt] => 2023-04-18 15:17:41
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 11:50:00
                            [post_modified_gmt] => 2023-06-27 11:50:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9874
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [141] => WP_Post Object
                        (
                            [ID] => 9873
                            [post_author] => 5
                            [post_date] => 2023-04-18 14:52:22
                            [post_date_gmt] => 2023-04-18 14:52:22
                            [post_content] => 
                            [post_title] => DNDi Template Development Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-development-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 11:44:53
                            [post_modified_gmt] => 2023-06-27 11:44:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9873
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [142] => WP_Post Object
                        (
                            [ID] => 9872
                            [post_author] => 5
                            [post_date] => 2023-04-18 13:17:39
                            [post_date_gmt] => 2023-04-18 13:17:39
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 14:24:05
                            [post_modified_gmt] => 2023-06-27 14:24:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9872
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [143] => WP_Post Object
                        (
                            [ID] => 9871
                            [post_author] => 5
                            [post_date] => 2023-04-18 10:57:25
                            [post_date_gmt] => 2023-04-18 10:57:25
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 14:25:17
                            [post_modified_gmt] => 2023-06-27 14:25:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9871
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [144] => WP_Post Object
                        (
                            [ID] => 9870
                            [post_author] => 5
                            [post_date] => 2023-04-18 10:46:43
                            [post_date_gmt] => 2023-04-18 10:46:43
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 14:24:37
                            [post_modified_gmt] => 2023-06-27 14:24:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9870
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [145] => WP_Post Object
                        (
                            [ID] => 9869
                            [post_author] => 5
                            [post_date] => 2023-04-18 10:43:52
                            [post_date_gmt] => 2023-04-18 10:43:52
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 14:19:16
                            [post_modified_gmt] => 2023-06-27 14:19:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [146] => WP_Post Object
                        (
                            [ID] => 9868
                            [post_author] => 5
                            [post_date] => 2023-04-18 10:40:41
                            [post_date_gmt] => 2023-04-18 10:40:41
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 14:20:07
                            [post_modified_gmt] => 2023-06-27 14:20:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9868
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [147] => WP_Post Object
                        (
                            [ID] => 9867
                            [post_author] => 5
                            [post_date] => 2023-04-18 10:21:23
                            [post_date_gmt] => 2023-04-18 10:21:23
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 14:02:27
                            [post_modified_gmt] => 2023-06-27 14:02:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9867
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [148] => WP_Post Object
                        (
                            [ID] => 9866
                            [post_author] => 5
                            [post_date] => 2023-04-18 10:10:55
                            [post_date_gmt] => 2023-04-18 10:10:55
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:59:41
                            [post_modified_gmt] => 2023-06-27 13:59:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9866
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [149] => WP_Post Object
                        (
                            [ID] => 9865
                            [post_author] => 5
                            [post_date] => 2023-04-18 09:13:30
                            [post_date_gmt] => 2023-04-18 09:13:30
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 08:25:18
                            [post_modified_gmt] => 2023-10-17 08:25:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9865
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [150] => WP_Post Object
                        (
                            [ID] => 9863
                            [post_author] => 5
                            [post_date] => 2023-04-18 08:21:11
                            [post_date_gmt] => 2023-04-18 08:21:11
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-17 08:24:50
                            [post_modified_gmt] => 2023-10-17 08:24:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9863
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [151] => WP_Post Object
                        (
                            [ID] => 9864
                            [post_author] => 5
                            [post_date] => 2023-04-18 07:54:00
                            [post_date_gmt] => 2023-04-18 07:54:00
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 14:08:29
                            [post_modified_gmt] => 2023-06-27 14:08:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9864
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [152] => WP_Post Object
                        (
                            [ID] => 9862
                            [post_author] => 5
                            [post_date] => 2023-04-17 14:28:56
                            [post_date_gmt] => 2023-04-17 14:28:56
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:49:26
                            [post_modified_gmt] => 2023-06-27 13:49:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9862
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [153] => WP_Post Object
                        (
                            [ID] => 9861
                            [post_author] => 5
                            [post_date] => 2023-04-17 14:18:47
                            [post_date_gmt] => 2023-04-17 14:18:47
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:48:20
                            [post_modified_gmt] => 2023-06-27 13:48:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9861
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [154] => WP_Post Object
                        (
                            [ID] => 9860
                            [post_author] => 5
                            [post_date] => 2023-04-14 14:35:29
                            [post_date_gmt] => 2023-04-14 14:35:29
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:12:45
                            [post_modified_gmt] => 2023-11-10 14:12:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9860
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [155] => WP_Post Object
                        (
                            [ID] => 9859
                            [post_author] => 5
                            [post_date] => 2023-04-14 13:08:09
                            [post_date_gmt] => 2023-04-14 13:08:09
                            [post_content] => 
                            [post_title] => DNDi Template Research Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dndi-template-research-collaboration-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 13:45:17
                            [post_modified_gmt] => 2023-06-27 13:45:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9859
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [156] => WP_Post Object
                        (
                            [ID] => 9057
                            [post_author] => 5
                            [post_date] => 2023-03-06 10:34:15
                            [post_date_gmt] => 2023-03-06 10:34:15
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:07:43
                            [post_modified_gmt] => 2023-06-20 11:07:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9057
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [157] => WP_Post Object
                        (
                            [ID] => 9056
                            [post_author] => 5
                            [post_date] => 2023-03-06 09:37:28
                            [post_date_gmt] => 2023-03-06 09:37:28
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:48:18
                            [post_modified_gmt] => 2023-06-20 11:48:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9056
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [158] => WP_Post Object
                        (
                            [ID] => 9055
                            [post_author] => 5
                            [post_date] => 2023-03-03 16:02:36
                            [post_date_gmt] => 2023-03-03 16:02:36
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:43:03
                            [post_modified_gmt] => 2023-06-20 11:43:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9055
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [159] => WP_Post Object
                        (
                            [ID] => 9054
                            [post_author] => 5
                            [post_date] => 2023-03-03 15:46:50
                            [post_date_gmt] => 2023-03-03 15:46:50
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:50:04
                            [post_modified_gmt] => 2023-06-20 11:50:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9054
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [160] => WP_Post Object
                        (
                            [ID] => 9053
                            [post_author] => 5
                            [post_date] => 2023-03-03 15:34:51
                            [post_date_gmt] => 2023-03-03 15:34:51
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:39:18
                            [post_modified_gmt] => 2023-06-20 11:39:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9053
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [161] => WP_Post Object
                        (
                            [ID] => 9052
                            [post_author] => 5
                            [post_date] => 2023-03-03 15:20:20
                            [post_date_gmt] => 2023-03-03 15:20:20
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:38:44
                            [post_modified_gmt] => 2023-06-20 11:38:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9052
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [162] => WP_Post Object
                        (
                            [ID] => 9051
                            [post_author] => 5
                            [post_date] => 2023-03-03 15:03:06
                            [post_date_gmt] => 2023-03-03 15:03:06
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:34:55
                            [post_modified_gmt] => 2023-06-20 11:34:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [163] => WP_Post Object
                        (
                            [ID] => 9050
                            [post_author] => 5
                            [post_date] => 2023-03-03 14:35:41
                            [post_date_gmt] => 2023-03-03 14:35:41
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:09:06
                            [post_modified_gmt] => 2023-06-20 11:09:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9050
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [164] => WP_Post Object
                        (
                            [ID] => 9049
                            [post_author] => 5
                            [post_date] => 2023-03-03 14:27:14
                            [post_date_gmt] => 2023-03-03 14:27:14
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:14:43
                            [post_modified_gmt] => 2023-06-20 11:14:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9049
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [165] => WP_Post Object
                        (
                            [ID] => 9048
                            [post_author] => 5
                            [post_date] => 2023-03-03 14:14:36
                            [post_date_gmt] => 2023-03-03 14:14:36
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:13:03
                            [post_modified_gmt] => 2023-06-20 11:13:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9048
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [166] => WP_Post Object
                        (
                            [ID] => 9047
                            [post_author] => 5
                            [post_date] => 2023-03-03 13:52:18
                            [post_date_gmt] => 2023-03-03 13:52:18
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:50:26
                            [post_modified_gmt] => 2023-11-10 13:50:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9047
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [167] => WP_Post Object
                        (
                            [ID] => 9036
                            [post_author] => 5
                            [post_date] => 2023-03-03 13:07:34
                            [post_date_gmt] => 2023-03-03 13:07:34
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:34:10
                            [post_modified_gmt] => 2023-06-20 11:34:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9036
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [168] => WP_Post Object
                        (
                            [ID] => 9035
                            [post_author] => 5
                            [post_date] => 2023-03-03 12:50:57
                            [post_date_gmt] => 2023-03-03 12:50:57
                            [post_content] => 
                            [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 11:32:25
                            [post_modified_gmt] => 2023-06-20 11:32:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9035
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [169] => WP_Post Object
                        (
                            [ID] => 3910
                            [post_author] => 5
                            [post_date] => 2022-12-15 14:44:16
                            [post_date_gmt] => 2022-12-15 14:44:16
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:21:46
                            [post_modified_gmt] => 2023-08-02 15:21:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3910
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [170] => WP_Post Object
                        (
                            [ID] => 5806
                            [post_author] => 5
                            [post_date] => 2022-09-28 14:56:08
                            [post_date_gmt] => 2022-09-28 14:56:08
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-28 14:56:08
                            [post_modified_gmt] => 2022-09-28 14:56:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [171] => WP_Post Object
                        (
                            [ID] => 5805
                            [post_author] => 5
                            [post_date] => 2022-09-28 14:49:39
                            [post_date_gmt] => 2022-09-28 14:49:39
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:32:48
                            [post_modified_gmt] => 2023-05-04 11:32:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [172] => WP_Post Object
                        (
                            [ID] => 5804
                            [post_author] => 5
                            [post_date] => 2022-09-28 08:20:57
                            [post_date_gmt] => 2022-09-28 08:20:57
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-28 08:20:57
                            [post_modified_gmt] => 2022-09-28 08:20:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [173] => WP_Post Object
                        (
                            [ID] => 5803
                            [post_author] => 5
                            [post_date] => 2022-09-28 08:09:22
                            [post_date_gmt] => 2022-09-28 08:09:22
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-28 08:09:22
                            [post_modified_gmt] => 2022-09-28 08:09:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5803
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [174] => WP_Post Object
                        (
                            [ID] => 5802
                            [post_author] => 5
                            [post_date] => 2022-09-28 08:03:24
                            [post_date_gmt] => 2022-09-28 08:03:24
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 09:02:04
                            [post_modified_gmt] => 2022-09-29 09:02:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [175] => WP_Post Object
                        (
                            [ID] => 5800
                            [post_author] => 5
                            [post_date] => 2022-09-28 07:45:10
                            [post_date_gmt] => 2022-09-28 07:45:10
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:39:57
                            [post_modified_gmt] => 2023-11-10 14:39:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [176] => WP_Post Object
                        (
                            [ID] => 5799
                            [post_author] => 5
                            [post_date] => 2022-09-27 13:35:42
                            [post_date_gmt] => 2022-09-27 13:35:42
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 13:35:42
                            [post_modified_gmt] => 2022-09-27 13:35:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5799
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [177] => WP_Post Object
                        (
                            [ID] => 5798
                            [post_author] => 5
                            [post_date] => 2022-09-27 13:11:04
                            [post_date_gmt] => 2022-09-27 13:11:04
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 07:20:44
                            [post_modified_gmt] => 2022-09-29 07:20:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [178] => WP_Post Object
                        (
                            [ID] => 5790
                            [post_author] => 5
                            [post_date] => 2022-09-27 09:01:33
                            [post_date_gmt] => 2022-09-27 09:01:33
                            [post_content] => 
                            [post_title] => Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-tdf-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:24:23
                            [post_modified_gmt] => 2023-05-04 11:24:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5790
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [179] => WP_Post Object
                        (
                            [ID] => 5429
                            [post_author] => 5
                            [post_date] => 2022-07-25 06:51:00
                            [post_date_gmt] => 2022-07-25 06:51:00
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 12:00:45
                            [post_modified_gmt] => 2023-05-04 12:00:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5429
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [180] => WP_Post Object
                        (
                            [ID] => 5286
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:44:08
                            [post_date_gmt] => 2022-07-08 13:44:08
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-12 11:31:31
                            [post_modified_gmt] => 2022-07-12 11:31:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5286
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [181] => WP_Post Object
                        (
                            [ID] => 5285
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:33:14
                            [post_date_gmt] => 2022-07-08 13:33:14
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:41:56
                            [post_modified_gmt] => 2023-04-27 11:41:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5285
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [182] => WP_Post Object
                        (
                            [ID] => 5284
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:17:26
                            [post_date_gmt] => 2022-07-08 13:17:26
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-12 11:30:52
                            [post_modified_gmt] => 2022-07-12 11:30:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5284
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [183] => WP_Post Object
                        (
                            [ID] => 5283
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:03:43
                            [post_date_gmt] => 2022-07-08 13:03:43
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-12 11:25:34
                            [post_modified_gmt] => 2022-07-12 11:25:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5283
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [184] => WP_Post Object
                        (
                            [ID] => 5282
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:00:08
                            [post_date_gmt] => 2022-07-08 13:00:08
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:39:53
                            [post_modified_gmt] => 2023-04-27 11:39:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5282
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [185] => WP_Post Object
                        (
                            [ID] => 5281
                            [post_author] => 5
                            [post_date] => 2022-07-08 12:00:54
                            [post_date_gmt] => 2022-07-08 12:00:54
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-18 11:48:44
                            [post_modified_gmt] => 2023-07-18 11:48:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5281
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [186] => WP_Post Object
                        (
                            [ID] => 5280
                            [post_author] => 5
                            [post_date] => 2022-07-08 11:46:11
                            [post_date_gmt] => 2022-07-08 11:46:11
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:03:14
                            [post_modified_gmt] => 2022-10-12 11:03:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5280
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [187] => WP_Post Object
                        (
                            [ID] => 5279
                            [post_author] => 5
                            [post_date] => 2022-07-08 10:36:09
                            [post_date_gmt] => 2022-07-08 10:36:09
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-02-03 13:44:48
                            [post_modified_gmt] => 2023-02-03 13:44:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5279
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [188] => WP_Post Object
                        (
                            [ID] => 5278
                            [post_author] => 5
                            [post_date] => 2022-07-08 10:25:20
                            [post_date_gmt] => 2022-07-08 10:25:20
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-18 11:50:51
                            [post_modified_gmt] => 2023-07-18 11:50:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5278
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [189] => WP_Post Object
                        (
                            [ID] => 5277
                            [post_author] => 5
                            [post_date] => 2022-07-08 10:12:53
                            [post_date_gmt] => 2022-07-08 10:12:53
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-11 13:26:16
                            [post_modified_gmt] => 2022-07-11 13:26:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5277
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [190] => WP_Post Object
                        (
                            [ID] => 5276
                            [post_author] => 5
                            [post_date] => 2022-07-08 10:04:48
                            [post_date_gmt] => 2022-07-08 10:04:48
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 09:53:02
                            [post_modified_gmt] => 2022-09-27 09:53:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5276
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [191] => WP_Post Object
                        (
                            [ID] => 5275
                            [post_author] => 5
                            [post_date] => 2022-07-08 09:34:04
                            [post_date_gmt] => 2022-07-08 09:34:04
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-11 12:22:08
                            [post_modified_gmt] => 2022-07-11 12:22:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5275
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [192] => WP_Post Object
                        (
                            [ID] => 5274
                            [post_author] => 5
                            [post_date] => 2022-07-08 09:14:56
                            [post_date_gmt] => 2022-07-08 09:14:56
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:48:27
                            [post_modified_gmt] => 2022-10-12 12:48:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5274
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [193] => WP_Post Object
                        (
                            [ID] => 5273
                            [post_author] => 5
                            [post_date] => 2022-07-08 08:33:17
                            [post_date_gmt] => 2022-07-08 08:33:17
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:01:00
                            [post_modified_gmt] => 2023-11-10 15:01:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5273
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [194] => WP_Post Object
                        (
                            [ID] => 5272
                            [post_author] => 5
                            [post_date] => 2022-07-08 08:28:02
                            [post_date_gmt] => 2022-07-08 08:28:02
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:36:50
                            [post_modified_gmt] => 2023-04-27 11:36:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5272
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [195] => WP_Post Object
                        (
                            [ID] => 5271
                            [post_author] => 5
                            [post_date] => 2022-07-08 08:21:14
                            [post_date_gmt] => 2022-07-08 08:21:14
                            [post_content] => 
                            [post_title] => Shionogi - GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:44:53
                            [post_modified_gmt] => 2022-07-13 13:44:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5271
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [196] => WP_Post Object
                        (
                            [ID] => 5270
                            [post_author] => 5
                            [post_date] => 2022-07-08 08:12:42
                            [post_date_gmt] => 2022-07-08 08:12:42
                            [post_content] => 
                            [post_title] => Shionogi - GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-18 11:56:47
                            [post_modified_gmt] => 2023-07-18 11:56:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5270
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [197] => WP_Post Object
                        (
                            [ID] => 5269
                            [post_author] => 5
                            [post_date] => 2022-07-08 07:47:02
                            [post_date_gmt] => 2022-07-08 07:47:02
                            [post_content] => 
                            [post_title] => Shionogi - GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 11:52:37
                            [post_modified_gmt] => 2022-07-13 11:52:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5269
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [198] => WP_Post Object
                        (
                            [ID] => 5123
                            [post_author] => 5
                            [post_date] => 2022-06-29 15:28:35
                            [post_date_gmt] => 2022-06-29 15:28:35
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:42:31
                            [post_modified_gmt] => 2023-11-10 14:42:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [199] => WP_Post Object
                        (
                            [ID] => 5122
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:42:34
                            [post_date_gmt] => 2022-06-29 14:42:34
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 5122
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:22
                            [post_modified_gmt] => 2023-09-18 11:57:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [200] => WP_Post Object
                        (
                            [ID] => 5121
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:38:19
                            [post_date_gmt] => 2022-06-29 14:38:19
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:28
                            [post_modified_gmt] => 2023-09-18 11:57:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5121
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [201] => WP_Post Object
                        (
                            [ID] => 5120
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:30:21
                            [post_date_gmt] => 2022-06-29 14:30:21
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:56:50
                            [post_modified_gmt] => 2023-09-18 11:56:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [202] => WP_Post Object
                        (
                            [ID] => 5119
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:09:28
                            [post_date_gmt] => 2022-06-29 14:09:28
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:56:57
                            [post_modified_gmt] => 2023-09-18 11:56:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5119
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [203] => WP_Post Object
                        (
                            [ID] => 5118
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:05:52
                            [post_date_gmt] => 2022-06-29 14:05:52
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:41
                            [post_modified_gmt] => 2023-09-18 11:57:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5118
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [204] => WP_Post Object
                        (
                            [ID] => 5117
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:02:42
                            [post_date_gmt] => 2022-06-29 14:02:42
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:46
                            [post_modified_gmt] => 2023-09-18 11:57:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5117
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [205] => WP_Post Object
                        (
                            [ID] => 5116
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:00:58
                            [post_date_gmt] => 2022-06-29 14:00:58
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:51
                            [post_modified_gmt] => 2023-09-18 11:57:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5116
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [206] => WP_Post Object
                        (
                            [ID] => 5115
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:52:08
                            [post_date_gmt] => 2022-06-29 13:52:08
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:56
                            [post_modified_gmt] => 2023-09-18 11:57:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5115
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [207] => WP_Post Object
                        (
                            [ID] => 5114
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:46:01
                            [post_date_gmt] => 2022-06-29 13:46:01
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:00
                            [post_modified_gmt] => 2023-09-18 11:58:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5114
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [208] => WP_Post Object
                        (
                            [ID] => 5113
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:33:56
                            [post_date_gmt] => 2022-06-29 13:33:56
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:05
                            [post_modified_gmt] => 2023-09-18 11:58:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5113
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [209] => WP_Post Object
                        (
                            [ID] => 5112
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:04:55
                            [post_date_gmt] => 2022-06-29 13:04:55
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:11
                            [post_modified_gmt] => 2023-09-18 11:58:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5112
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [210] => WP_Post Object
                        (
                            [ID] => 5111
                            [post_author] => 5
                            [post_date] => 2022-06-29 12:40:35
                            [post_date_gmt] => 2022-06-29 12:40:35
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:17
                            [post_modified_gmt] => 2023-09-18 11:58:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5111
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [211] => WP_Post Object
                        (
                            [ID] => 4869
                            [post_author] => 5
                            [post_date] => 2022-06-07 10:16:47
                            [post_date_gmt] => 2022-06-07 10:16:47
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:37:17
                            [post_modified_gmt] => 2023-06-20 12:37:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [212] => WP_Post Object
                        (
                            [ID] => 4868
                            [post_author] => 5
                            [post_date] => 2022-06-07 09:30:21
                            [post_date_gmt] => 2022-06-07 09:30:21
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:32:18
                            [post_modified_gmt] => 2023-06-20 12:32:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4868
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [213] => WP_Post Object
                        (
                            [ID] => 4867
                            [post_author] => 5
                            [post_date] => 2022-06-07 09:14:39
                            [post_date_gmt] => 2022-06-07 09:14:39
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 13:29:36
                            [post_modified_gmt] => 2023-06-20 13:29:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4867
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [214] => WP_Post Object
                        (
                            [ID] => 4866
                            [post_author] => 5
                            [post_date] => 2022-06-07 08:53:11
                            [post_date_gmt] => 2022-06-07 08:53:11
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 15:19:16
                            [post_modified_gmt] => 2023-06-20 15:19:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4866
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [215] => WP_Post Object
                        (
                            [ID] => 4865
                            [post_author] => 5
                            [post_date] => 2022-06-07 08:46:16
                            [post_date_gmt] => 2022-06-07 08:46:16
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 13:25:20
                            [post_modified_gmt] => 2023-06-20 13:25:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4865
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [216] => WP_Post Object
                        (
                            [ID] => 4864
                            [post_author] => 5
                            [post_date] => 2022-06-07 08:29:48
                            [post_date_gmt] => 2022-06-07 08:29:48
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:36:02
                            [post_modified_gmt] => 2023-06-20 12:36:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4864
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [217] => WP_Post Object
                        (
                            [ID] => 4863
                            [post_author] => 5
                            [post_date] => 2022-06-06 14:26:47
                            [post_date_gmt] => 2022-06-06 14:26:47
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:54:15
                            [post_modified_gmt] => 2023-11-10 13:54:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4863
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [218] => WP_Post Object
                        (
                            [ID] => 4862
                            [post_author] => 5
                            [post_date] => 2022-06-06 14:20:32
                            [post_date_gmt] => 2022-06-06 14:20:32
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 15:22:08
                            [post_modified_gmt] => 2023-06-20 15:22:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4862
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [219] => WP_Post Object
                        (
                            [ID] => 4861
                            [post_author] => 5
                            [post_date] => 2022-06-06 13:55:49
                            [post_date_gmt] => 2022-06-06 13:55:49
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 13:08:02
                            [post_modified_gmt] => 2023-06-20 13:08:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4861
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [220] => WP_Post Object
                        (
                            [ID] => 4860
                            [post_author] => 5
                            [post_date] => 2022-06-06 13:12:22
                            [post_date_gmt] => 2022-06-06 13:12:22
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 13:26:30
                            [post_modified_gmt] => 2023-06-20 13:26:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4860
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [221] => WP_Post Object
                        (
                            [ID] => 4859
                            [post_author] => 5
                            [post_date] => 2022-06-06 12:38:41
                            [post_date_gmt] => 2022-06-06 12:38:41
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 13:14:16
                            [post_modified_gmt] => 2023-06-20 13:14:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4859
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [222] => WP_Post Object
                        (
                            [ID] => 4858
                            [post_author] => 5
                            [post_date] => 2022-06-02 12:35:22
                            [post_date_gmt] => 2022-06-02 12:35:22
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:29:49
                            [post_modified_gmt] => 2023-06-20 12:29:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4858
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [223] => WP_Post Object
                        (
                            [ID] => 4855
                            [post_author] => 5
                            [post_date] => 2022-06-01 11:59:15
                            [post_date_gmt] => 2022-06-01 11:59:15
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:39:39
                            [post_modified_gmt] => 2022-08-11 09:39:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4855
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [224] => WP_Post Object
                        (
                            [ID] => 4853
                            [post_author] => 5
                            [post_date] => 2022-06-01 11:47:22
                            [post_date_gmt] => 2022-06-01 11:47:22
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:40:07
                            [post_modified_gmt] => 2022-08-11 09:40:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4853
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [225] => WP_Post Object
                        (
                            [ID] => 4850
                            [post_author] => 5
                            [post_date] => 2022-05-31 10:27:15
                            [post_date_gmt] => 2022-05-31 10:27:15
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:06:38
                            [post_modified_gmt] => 2022-10-12 11:06:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4850
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [226] => WP_Post Object
                        (
                            [ID] => 4849
                            [post_author] => 5
                            [post_date] => 2022-05-31 10:09:48
                            [post_date_gmt] => 2022-05-31 10:09:48
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-15 06:36:36
                            [post_modified_gmt] => 2023-06-15 06:36:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4849
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [227] => WP_Post Object
                        (
                            [ID] => 4848
                            [post_author] => 5
                            [post_date] => 2022-05-31 09:49:03
                            [post_date_gmt] => 2022-05-31 09:49:03
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 10:11:26
                            [post_modified_gmt] => 2022-05-31 10:11:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4848
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [228] => WP_Post Object
                        (
                            [ID] => 4847
                            [post_author] => 5
                            [post_date] => 2022-05-31 09:19:59
                            [post_date_gmt] => 2022-05-31 09:19:59
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 09:19:59
                            [post_modified_gmt] => 2022-05-31 09:19:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4847
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [229] => WP_Post Object
                        (
                            [ID] => 4846
                            [post_author] => 5
                            [post_date] => 2022-05-31 09:13:07
                            [post_date_gmt] => 2022-05-31 09:13:07
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 09:13:58
                            [post_modified_gmt] => 2022-05-31 09:13:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4846
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [230] => WP_Post Object
                        (
                            [ID] => 4845
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:57:11
                            [post_date_gmt] => 2022-05-31 08:57:11
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 09:01:01
                            [post_modified_gmt] => 2022-05-31 09:01:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4845
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [231] => WP_Post Object
                        (
                            [ID] => 4844
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:52:57
                            [post_date_gmt] => 2022-05-31 08:52:57
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 08:52:57
                            [post_modified_gmt] => 2022-05-31 08:52:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4844
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [232] => WP_Post Object
                        (
                            [ID] => 4843
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:47:53
                            [post_date_gmt] => 2022-05-31 08:47:53
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:19:47
                            [post_modified_gmt] => 2022-09-29 11:19:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4843
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [233] => WP_Post Object
                        (
                            [ID] => 4842
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:33:58
                            [post_date_gmt] => 2022-05-31 08:33:58
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 12:37:54
                            [post_modified_gmt] => 2023-04-27 12:37:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4842
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [234] => WP_Post Object
                        (
                            [ID] => 4841
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:22:01
                            [post_date_gmt] => 2022-05-31 08:22:01
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:51:15
                            [post_modified_gmt] => 2022-10-12 12:51:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4841
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [235] => WP_Post Object
                        (
                            [ID] => 4840
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:10:32
                            [post_date_gmt] => 2022-05-31 08:10:32
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:23:05
                            [post_modified_gmt] => 2023-11-10 14:23:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4840
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [236] => WP_Post Object
                        (
                            [ID] => 4838
                            [post_author] => 5
                            [post_date] => 2022-05-27 15:01:58
                            [post_date_gmt] => 2022-05-27 15:01:58
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 09:20:03
                            [post_modified_gmt] => 2023-11-10 09:20:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4838
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [237] => WP_Post Object
                        (
                            [ID] => 4837
                            [post_author] => 5
                            [post_date] => 2022-05-27 14:43:04
                            [post_date_gmt] => 2022-05-27 14:43:04
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 12:57:32
                            [post_modified_gmt] => 2022-07-13 12:57:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4837
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [238] => WP_Post Object
                        (
                            [ID] => 4835
                            [post_author] => 5
                            [post_date] => 2022-05-27 14:00:10
                            [post_date_gmt] => 2022-05-27 14:00:10
                            [post_content] => 
                            [post_title] => Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 09:43:34
                            [post_modified_gmt] => 2023-05-05 09:43:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4835
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [239] => WP_Post Object
                        (
                            [ID] => 4834
                            [post_author] => 5
                            [post_date] => 2022-05-27 13:26:16
                            [post_date_gmt] => 2022-05-27 13:26:16
                            [post_content] => 
                            [post_title] => Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 09:28:10
                            [post_modified_gmt] => 2022-07-13 09:28:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4834
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [240] => WP_Post Object
                        (
                            [ID] => 4808
                            [post_author] => 5
                            [post_date] => 2022-05-24 09:09:54
                            [post_date_gmt] => 2022-05-24 09:09:54
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:13:53
                            [post_modified_gmt] => 2023-09-27 10:13:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [241] => WP_Post Object
                        (
                            [ID] => 4807
                            [post_author] => 5
                            [post_date] => 2022-05-24 09:02:55
                            [post_date_gmt] => 2022-05-24 09:02:55
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:32:19
                            [post_modified_gmt] => 2023-09-27 11:32:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [242] => WP_Post Object
                        (
                            [ID] => 4806
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:59:08
                            [post_date_gmt] => 2022-05-24 08:59:08
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:11:24
                            [post_modified_gmt] => 2023-09-27 10:11:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [243] => WP_Post Object
                        (
                            [ID] => 4805
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:53:12
                            [post_date_gmt] => 2022-05-24 08:53:12
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:34:37
                            [post_modified_gmt] => 2023-09-27 11:34:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [244] => WP_Post Object
                        (
                            [ID] => 4804
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:40:15
                            [post_date_gmt] => 2022-05-24 08:40:15
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:33:40
                            [post_modified_gmt] => 2023-09-27 11:33:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [245] => WP_Post Object
                        (
                            [ID] => 4802
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:24:23
                            [post_date_gmt] => 2022-05-24 08:24:23
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:31:31
                            [post_modified_gmt] => 2023-09-27 11:31:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [246] => WP_Post Object
                        (
                            [ID] => 4801
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:19:21
                            [post_date_gmt] => 2022-05-24 08:19:21
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:15:07
                            [post_modified_gmt] => 2023-09-27 10:15:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [247] => WP_Post Object
                        (
                            [ID] => 4800
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:07:39
                            [post_date_gmt] => 2022-05-24 08:07:39
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:13:19
                            [post_modified_gmt] => 2023-09-27 10:13:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [248] => WP_Post Object
                        (
                            [ID] => 4798
                            [post_author] => 5
                            [post_date] => 2022-05-23 14:11:13
                            [post_date_gmt] => 2022-05-23 14:11:13
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:12:22
                            [post_modified_gmt] => 2023-09-27 10:12:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [249] => WP_Post Object
                        (
                            [ID] => 4797
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:57
                            [post_date_gmt] => 2022-05-23 13:54:57
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:30:35
                            [post_modified_gmt] => 2023-09-27 11:30:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [250] => WP_Post Object
                        (
                            [ID] => 4796
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:05
                            [post_date_gmt] => 2022-05-23 13:54:05
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:00:31
                            [post_modified_gmt] => 2023-09-27 10:00:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [251] => WP_Post Object
                        (
                            [ID] => 4661
                            [post_author] => 5
                            [post_date] => 2022-04-20 08:13:06
                            [post_date_gmt] => 2022-04-20 08:13:06
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:03:07
                            [post_modified_gmt] => 2023-07-10 15:03:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4661
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [252] => WP_Post Object
                        (
                            [ID] => 4491
                            [post_author] => 5
                            [post_date] => 2022-03-17 15:42:04
                            [post_date_gmt] => 2022-03-17 15:42:04
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:33:21
                            [post_modified_gmt] => 2023-06-21 09:33:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4491
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [253] => WP_Post Object
                        (
                            [ID] => 4490
                            [post_author] => 5
                            [post_date] => 2022-03-17 15:37:26
                            [post_date_gmt] => 2022-03-17 15:37:26
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:05:15
                            [post_modified_gmt] => 2023-06-21 09:05:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4490
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [254] => WP_Post Object
                        (
                            [ID] => 4489
                            [post_author] => 5
                            [post_date] => 2022-03-17 15:33:45
                            [post_date_gmt] => 2022-03-17 15:33:45
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:13:51
                            [post_modified_gmt] => 2023-06-21 09:13:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4489
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [255] => WP_Post Object
                        (
                            [ID] => 4488
                            [post_author] => 5
                            [post_date] => 2022-03-17 15:11:54
                            [post_date_gmt] => 2022-03-17 15:11:54
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:42:09
                            [post_modified_gmt] => 2023-06-21 09:42:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4488
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [256] => WP_Post Object
                        (
                            [ID] => 4487
                            [post_author] => 5
                            [post_date] => 2022-03-17 14:58:23
                            [post_date_gmt] => 2022-03-17 14:58:23
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:45:11
                            [post_modified_gmt] => 2023-06-21 09:45:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4487
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [257] => WP_Post Object
                        (
                            [ID] => 4486
                            [post_author] => 5
                            [post_date] => 2022-03-17 14:50:08
                            [post_date_gmt] => 2022-03-17 14:50:08
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:43:10
                            [post_modified_gmt] => 2023-06-21 09:43:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4486
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [258] => WP_Post Object
                        (
                            [ID] => 4485
                            [post_author] => 5
                            [post_date] => 2022-03-17 14:43:27
                            [post_date_gmt] => 2022-03-17 14:43:27
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:39:42
                            [post_modified_gmt] => 2023-06-21 09:39:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4485
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [259] => WP_Post Object
                        (
                            [ID] => 4484
                            [post_author] => 5
                            [post_date] => 2022-03-17 13:56:19
                            [post_date_gmt] => 2022-03-17 13:56:19
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:32:11
                            [post_modified_gmt] => 2023-06-21 09:32:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4484
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [260] => WP_Post Object
                        (
                            [ID] => 4483
                            [post_author] => 5
                            [post_date] => 2022-03-17 13:21:19
                            [post_date_gmt] => 2022-03-17 13:21:19
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:10:23
                            [post_modified_gmt] => 2023-06-21 09:10:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4483
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [261] => WP_Post Object
                        (
                            [ID] => 4482
                            [post_author] => 5
                            [post_date] => 2022-03-17 12:43:13
                            [post_date_gmt] => 2022-03-17 12:43:13
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:11:28
                            [post_modified_gmt] => 2023-06-21 09:11:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [262] => WP_Post Object
                        (
                            [ID] => 4481
                            [post_author] => 5
                            [post_date] => 2022-03-17 12:28:49
                            [post_date_gmt] => 2022-03-17 12:28:49
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:29:26
                            [post_modified_gmt] => 2023-06-21 09:29:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [263] => WP_Post Object
                        (
                            [ID] => 4469
                            [post_author] => 5
                            [post_date] => 2022-03-17 10:55:42
                            [post_date_gmt] => 2022-03-17 10:55:42
                            [post_content] => 
                            [post_title] => Cellscript - BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:27:49
                            [post_modified_gmt] => 2023-06-21 09:27:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4469
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [264] => WP_Post Object
                        (
                            [ID] => 4089
                            [post_author] => 5
                            [post_date] => 2022-01-11 13:35:45
                            [post_date_gmt] => 2022-01-11 13:35:45
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-09 10:10:12
                            [post_modified_gmt] => 2023-11-09 10:10:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4089
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [265] => WP_Post Object
                        (
                            [ID] => 4086
                            [post_author] => 5
                            [post_date] => 2022-01-11 12:13:55
                            [post_date_gmt] => 2022-01-11 12:13:55
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:30:30
                            [post_modified_gmt] => 2023-11-10 15:30:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4086
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [266] => WP_Post Object
                        (
                            [ID] => 4085
                            [post_author] => 5
                            [post_date] => 2022-01-11 12:01:14
                            [post_date_gmt] => 2022-01-11 12:01:14
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:28:50
                            [post_modified_gmt] => 2023-11-10 15:28:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4085
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [267] => WP_Post Object
                        (
                            [ID] => 4082
                            [post_author] => 5
                            [post_date] => 2022-01-11 09:06:56
                            [post_date_gmt] => 2022-01-11 09:06:56
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:28:15
                            [post_modified_gmt] => 2023-11-10 15:28:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4082
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [268] => WP_Post Object
                        (
                            [ID] => 4081
                            [post_author] => 5
                            [post_date] => 2022-01-11 08:42:56
                            [post_date_gmt] => 2022-01-11 08:42:56
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:26:15
                            [post_modified_gmt] => 2023-11-10 15:26:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4081
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [269] => WP_Post Object
                        (
                            [ID] => 4080
                            [post_author] => 5
                            [post_date] => 2022-01-11 08:32:58
                            [post_date_gmt] => 2022-01-11 08:32:58
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:20:46
                            [post_modified_gmt] => 2023-11-10 15:20:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4080
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [270] => WP_Post Object
                        (
                            [ID] => 4079
                            [post_author] => 5
                            [post_date] => 2022-01-11 08:07:49
                            [post_date_gmt] => 2022-01-11 08:07:49
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-24 13:03:54
                            [post_modified_gmt] => 2023-11-24 13:03:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4079
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [271] => WP_Post Object
                        (
                            [ID] => 4078
                            [post_author] => 5
                            [post_date] => 2022-01-11 07:42:00
                            [post_date_gmt] => 2022-01-11 07:42:00
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:22:01
                            [post_modified_gmt] => 2023-11-10 15:22:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4078
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [272] => WP_Post Object
                        (
                            [ID] => 4077
                            [post_author] => 5
                            [post_date] => 2022-01-11 07:20:11
                            [post_date_gmt] => 2022-01-11 07:20:11
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:02:23
                            [post_modified_gmt] => 2023-11-10 15:02:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4077
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [273] => WP_Post Object
                        (
                            [ID] => 4075
                            [post_author] => 5
                            [post_date] => 2022-01-11 05:59:46
                            [post_date_gmt] => 2022-01-11 05:59:46
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:24:30
                            [post_modified_gmt] => 2023-11-10 15:24:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4075
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [274] => WP_Post Object
                        (
                            [ID] => 4072
                            [post_author] => 5
                            [post_date] => 2022-01-08 13:16:04
                            [post_date_gmt] => 2022-01-08 13:16:04
                            [post_content] => 
                            [post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 15:23:59
                            [post_modified_gmt] => 2023-11-10 15:23:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4072
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [275] => WP_Post Object
                        (
                            [ID] => 4054
                            [post_author] => 5
                            [post_date] => 2022-01-03 11:45:52
                            [post_date_gmt] => 2022-01-03 11:45:52
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 14:45:07
                            [post_modified_gmt] => 2022-12-15 14:45:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4054
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [276] => WP_Post Object
                        (
                            [ID] => 4051
                            [post_author] => 5
                            [post_date] => 2022-01-03 11:01:41
                            [post_date_gmt] => 2022-01-03 11:01:41
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:38:45
                            [post_modified_gmt] => 2023-05-01 14:38:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [277] => WP_Post Object
                        (
                            [ID] => 4050
                            [post_author] => 5
                            [post_date] => 2022-01-03 10:49:32
                            [post_date_gmt] => 2022-01-03 10:49:32
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-03 10:56:55
                            [post_modified_gmt] => 2022-01-03 10:56:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4050
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [278] => WP_Post Object
                        (
                            [ID] => 4047
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:17:36
                            [post_date_gmt] => 2021-12-27 17:17:36
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:05:43
                            [post_modified_gmt] => 2023-01-04 16:05:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4047
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [279] => WP_Post Object
                        (
                            [ID] => 4046
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:10:47
                            [post_date_gmt] => 2021-12-27 17:10:47
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:13:16
                            [post_modified_gmt] => 2023-01-04 15:13:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4046
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [280] => WP_Post Object
                        (
                            [ID] => 4045
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:07:25
                            [post_date_gmt] => 2021-12-27 17:07:25
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:30:11
                            [post_modified_gmt] => 2023-04-27 11:30:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4045
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [281] => WP_Post Object
                        (
                            [ID] => 4043
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:47:54
                            [post_date_gmt] => 2021-12-27 16:47:54
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-27 16:47:54
                            [post_modified_gmt] => 2021-12-27 16:47:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4043
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [282] => WP_Post Object
                        (
                            [ID] => 4042
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:41:56
                            [post_date_gmt] => 2021-12-27 16:41:56
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:25:56
                            [post_modified_gmt] => 2022-09-29 12:25:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4042
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [283] => WP_Post Object
                        (
                            [ID] => 4041
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:28:21
                            [post_date_gmt] => 2021-12-27 16:28:21
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:55:03
                            [post_modified_gmt] => 2023-08-02 15:55:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4041
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [284] => WP_Post Object
                        (
                            [ID] => 4040
                            [post_author] => 5
                            [post_date] => 2021-12-27 15:24:04
                            [post_date_gmt] => 2021-12-27 15:24:04
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 11:34:34
                            [post_modified_gmt] => 2023-03-21 11:34:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4040
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [285] => WP_Post Object
                        (
                            [ID] => 4038
                            [post_author] => 5
                            [post_date] => 2021-12-27 15:08:30
                            [post_date_gmt] => 2021-12-27 15:08:30
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:35:46
                            [post_modified_gmt] => 2023-04-05 12:35:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4038
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [286] => WP_Post Object
                        (
                            [ID] => 4036
                            [post_author] => 5
                            [post_date] => 2021-12-26 17:01:45
                            [post_date_gmt] => 2021-12-26 17:01:45
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 11:31:29
                            [post_modified_gmt] => 2023-03-21 11:31:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4036
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [287] => WP_Post Object
                        (
                            [ID] => 4035
                            [post_author] => 5
                            [post_date] => 2021-12-26 16:47:36
                            [post_date_gmt] => 2021-12-26 16:47:36
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:28:18
                            [post_modified_gmt] => 2022-12-16 13:28:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4035
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [288] => WP_Post Object
                        (
                            [ID] => 4032
                            [post_author] => 5
                            [post_date] => 2021-12-26 16:32:27
                            [post_date_gmt] => 2021-12-26 16:32:27
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:37:25
                            [post_modified_gmt] => 2023-05-01 14:37:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4032
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [289] => WP_Post Object
                        (
                            [ID] => 4029
                            [post_author] => 5
                            [post_date] => 2021-12-21 12:22:08
                            [post_date_gmt] => 2021-12-21 12:22:08
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:36:19
                            [post_modified_gmt] => 2023-04-05 12:36:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4029
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [290] => WP_Post Object
                        (
                            [ID] => 4028
                            [post_author] => 5
                            [post_date] => 2021-12-21 11:55:28
                            [post_date_gmt] => 2021-12-21 11:55:28
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:35:05
                            [post_modified_gmt] => 2023-04-05 12:35:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4028
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [291] => WP_Post Object
                        (
                            [ID] => 4024
                            [post_author] => 5
                            [post_date] => 2021-12-15 15:33:17
                            [post_date_gmt] => 2021-12-15 15:33:17
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-15 15:33:17
                            [post_modified_gmt] => 2021-12-15 15:33:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4024
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [292] => WP_Post Object
                        (
                            [ID] => 4022
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:49:36
                            [post_date_gmt] => 2021-12-15 14:49:36
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-28 13:43:03
                            [post_modified_gmt] => 2023-04-28 13:43:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4022
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [293] => WP_Post Object
                        (
                            [ID] => 4021
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:31:00
                            [post_date_gmt] => 2021-12-15 14:31:00
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 13:06:46
                            [post_modified_gmt] => 2023-03-21 13:06:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4021
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [294] => WP_Post Object
                        (
                            [ID] => 4020
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:24:47
                            [post_date_gmt] => 2021-12-15 14:24:47
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:13:47
                            [post_modified_gmt] => 2023-01-04 15:13:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4020
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [295] => WP_Post Object
                        (
                            [ID] => 4017
                            [post_author] => 5
                            [post_date] => 2021-12-15 13:22:49
                            [post_date_gmt] => 2021-12-15 13:22:49
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-15 13:22:49
                            [post_modified_gmt] => 2021-12-15 13:22:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4017
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [296] => WP_Post Object
                        (
                            [ID] => 4016
                            [post_author] => 5
                            [post_date] => 2021-12-15 13:20:07
                            [post_date_gmt] => 2021-12-15 13:20:07
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 10:54:29
                            [post_modified_gmt] => 2022-09-29 10:54:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4016
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [297] => WP_Post Object
                        (
                            [ID] => 4014
                            [post_author] => 5
                            [post_date] => 2021-12-15 12:33:09
                            [post_date_gmt] => 2021-12-15 12:33:09
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 14:58:11
                            [post_modified_gmt] => 2023-09-27 14:58:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4014
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [298] => WP_Post Object
                        (
                            [ID] => 4013
                            [post_author] => 5
                            [post_date] => 2021-12-15 12:16:20
                            [post_date_gmt] => 2021-12-15 12:16:20
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 12:14:58
                            [post_modified_gmt] => 2023-09-27 12:14:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4013
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [299] => WP_Post Object
                        (
                            [ID] => 4011
                            [post_author] => 5
                            [post_date] => 2021-12-14 15:21:54
                            [post_date_gmt] => 2021-12-14 15:21:54
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 15:31:35
                            [post_modified_gmt] => 2023-09-27 15:31:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4011
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [300] => WP_Post Object
                        (
                            [ID] => 4009
                            [post_author] => 5
                            [post_date] => 2021-12-14 15:10:51
                            [post_date_gmt] => 2021-12-14 15:10:51
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:47:52
                            [post_modified_gmt] => 2023-09-27 11:47:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4009
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [301] => WP_Post Object
                        (
                            [ID] => 4007
                            [post_author] => 5
                            [post_date] => 2021-12-14 08:51:32
                            [post_date_gmt] => 2021-12-14 08:51:32
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:54:13
                            [post_modified_gmt] => 2023-09-27 11:54:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4007
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [302] => WP_Post Object
                        (
                            [ID] => 4006
                            [post_author] => 5
                            [post_date] => 2021-12-14 08:16:01
                            [post_date_gmt] => 2021-12-14 08:16:01
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 15:02:09
                            [post_modified_gmt] => 2023-09-27 15:02:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4006
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [303] => WP_Post Object
                        (
                            [ID] => 4004
                            [post_author] => 5
                            [post_date] => 2021-12-14 07:57:41
                            [post_date_gmt] => 2021-12-14 07:57:41
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:52:42
                            [post_modified_gmt] => 2023-09-27 11:52:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4004
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [304] => WP_Post Object
                        (
                            [ID] => 4003
                            [post_author] => 5
                            [post_date] => 2021-12-13 18:36:53
                            [post_date_gmt] => 2021-12-13 18:36:53
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 14:52:45
                            [post_modified_gmt] => 2023-09-27 14:52:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4003
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [305] => WP_Post Object
                        (
                            [ID] => 4002
                            [post_author] => 5
                            [post_date] => 2021-12-13 18:28:05
                            [post_date_gmt] => 2021-12-13 18:28:05
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:42:46
                            [post_modified_gmt] => 2023-09-27 11:42:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4002
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [306] => WP_Post Object
                        (
                            [ID] => 4001
                            [post_author] => 5
                            [post_date] => 2021-12-13 14:55:46
                            [post_date_gmt] => 2021-12-13 14:55:46
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 15:20:07
                            [post_modified_gmt] => 2023-09-27 15:20:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4001
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [307] => WP_Post Object
                        (
                            [ID] => 3997
                            [post_author] => 5
                            [post_date] => 2021-12-13 14:24:49
                            [post_date_gmt] => 2021-12-13 14:24:49
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 15:35:24
                            [post_modified_gmt] => 2023-09-27 15:35:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3997
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [308] => WP_Post Object
                        (
                            [ID] => 3914
                            [post_author] => 5
                            [post_date] => 2021-11-30 12:34:32
                            [post_date_gmt] => 2021-11-30 12:34:32
                            [post_content] => 
                            [post_title] => BMS – MPP Sublicense & Tech Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-bms-sublicense-tech-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:05:11
                            [post_modified_gmt] => 2023-09-18 12:05:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3914
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [309] => WP_Post Object
                        (
                            [ID] => 3909
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:29:28
                            [post_date_gmt] => 2021-11-22 13:29:28
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:06
                            [post_modified_gmt] => 2023-01-27 14:48:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [310] => WP_Post Object
                        (
                            [ID] => 3908
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:20:09
                            [post_date_gmt] => 2021-11-22 13:20:09
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:24
                            [post_modified_gmt] => 2023-01-27 14:48:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [311] => WP_Post Object
                        (
                            [ID] => 3907
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:07:49
                            [post_date_gmt] => 2021-11-22 13:07:49
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:44
                            [post_modified_gmt] => 2023-01-27 14:48:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [312] => WP_Post Object
                        (
                            [ID] => 3906
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:57:50
                            [post_date_gmt] => 2021-11-22 12:57:50
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:49:01
                            [post_modified_gmt] => 2023-01-27 14:49:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3906
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [313] => WP_Post Object
                        (
                            [ID] => 3904
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:20:20
                            [post_date_gmt] => 2021-11-22 12:20:20
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:47:28
                            [post_modified_gmt] => 2023-01-27 14:47:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3904
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [314] => WP_Post Object
                        (
                            [ID] => 3903
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:04:07
                            [post_date_gmt] => 2021-11-22 12:04:07
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:49:54
                            [post_modified_gmt] => 2023-01-27 14:49:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3903
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [315] => WP_Post Object
                        (
                            [ID] => 3901
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:42:55
                            [post_date_gmt] => 2021-11-22 11:42:55
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:50:40
                            [post_modified_gmt] => 2023-01-27 14:50:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3901
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [316] => WP_Post Object
                        (
                            [ID] => 3900
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:35:10
                            [post_date_gmt] => 2021-11-22 11:35:10
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:51:19
                            [post_modified_gmt] => 2023-01-27 14:51:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3900
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [317] => WP_Post Object
                        (
                            [ID] => 3899
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:24:36
                            [post_date_gmt] => 2021-11-22 11:24:36
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:17:52
                            [post_modified_gmt] => 2023-08-02 15:17:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3899
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [318] => WP_Post Object
                        (
                            [ID] => 3898
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:02:44
                            [post_date_gmt] => 2021-11-22 11:02:44
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:13
                            [post_modified_gmt] => 2023-01-27 14:52:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3898
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [319] => WP_Post Object
                        (
                            [ID] => 3897
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:34:34
                            [post_date_gmt] => 2021-11-22 10:34:34
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:36
                            [post_modified_gmt] => 2023-01-27 14:52:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3897
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [320] => WP_Post Object
                        (
                            [ID] => 3896
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:27:28
                            [post_date_gmt] => 2021-11-22 10:27:28
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:57
                            [post_modified_gmt] => 2023-01-27 14:52:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3896
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [321] => WP_Post Object
                        (
                            [ID] => 3895
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:20:20
                            [post_date_gmt] => 2021-11-22 10:20:20
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:41:01
                            [post_modified_gmt] => 2023-11-10 14:41:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3895
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [322] => WP_Post Object
                        (
                            [ID] => 3892
                            [post_author] => 5
                            [post_date] => 2021-11-19 13:53:26
                            [post_date_gmt] => 2021-11-19 13:53:26
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-18 11:44:42
                            [post_modified_gmt] => 2023-07-18 11:44:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [323] => WP_Post Object
                        (
                            [ID] => 3891
                            [post_author] => 5
                            [post_date] => 2021-11-19 13:11:12
                            [post_date_gmt] => 2021-11-19 13:11:12
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:54:03
                            [post_modified_gmt] => 2023-01-27 14:54:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3891
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [324] => WP_Post Object
                        (
                            [ID] => 3812
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:44:57
                            [post_date_gmt] => 2021-09-10 12:44:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:01:51
                            [post_modified_gmt] => 2023-07-10 17:01:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3812
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [325] => WP_Post Object
                        (
                            [ID] => 3810
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:21:33
                            [post_date_gmt] => 2021-09-10 12:21:33
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:55:36
                            [post_modified_gmt] => 2023-07-10 14:55:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3810
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [326] => WP_Post Object
                        (
                            [ID] => 3809
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:11:12
                            [post_date_gmt] => 2021-09-10 12:11:12
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:59:00
                            [post_modified_gmt] => 2023-07-10 14:59:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3809
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [327] => WP_Post Object
                        (
                            [ID] => 3808
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:59:11
                            [post_date_gmt] => 2021-09-10 11:59:11
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-14 10:56:31
                            [post_modified_gmt] => 2023-07-14 10:56:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [328] => WP_Post Object
                        (
                            [ID] => 3807
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:55:25
                            [post_date_gmt] => 2021-09-10 11:55:25
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:51:15
                            [post_modified_gmt] => 2023-07-10 14:51:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [329] => WP_Post Object
                        (
                            [ID] => 3806
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:47:18
                            [post_date_gmt] => 2021-09-10 11:47:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:43:52
                            [post_modified_gmt] => 2023-11-10 14:43:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [330] => WP_Post Object
                        (
                            [ID] => 3805
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:33:53
                            [post_date_gmt] => 2021-09-10 11:33:53
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:07:02
                            [post_modified_gmt] => 2023-07-10 17:07:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [331] => WP_Post Object
                        (
                            [ID] => 3804
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:20:59
                            [post_date_gmt] => 2021-09-10 11:20:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:08:42
                            [post_modified_gmt] => 2023-07-10 17:08:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [332] => WP_Post Object
                        (
                            [ID] => 3803
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:54:42
                            [post_date_gmt] => 2021-09-10 10:54:42
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 16:58:31
                            [post_modified_gmt] => 2023-07-10 16:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3803
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [333] => WP_Post Object
                        (
                            [ID] => 3802
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:45:57
                            [post_date_gmt] => 2021-09-10 10:45:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:08:48
                            [post_modified_gmt] => 2023-07-10 15:08:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [334] => WP_Post Object
                        (
                            [ID] => 3801
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:36:30
                            [post_date_gmt] => 2021-09-10 10:36:30
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:57:56
                            [post_modified_gmt] => 2023-07-10 14:57:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [335] => WP_Post Object
                        (
                            [ID] => 3800
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:25:59
                            [post_date_gmt] => 2021-09-10 10:25:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:05:04
                            [post_modified_gmt] => 2023-07-10 15:05:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [336] => WP_Post Object
                        (
                            [ID] => 3799
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:07:18
                            [post_date_gmt] => 2021-09-10 10:07:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:01:09
                            [post_modified_gmt] => 2023-07-10 15:01:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3799
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [337] => WP_Post Object
                        (
                            [ID] => 3798
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:02:07
                            [post_date_gmt] => 2021-09-10 10:02:07
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:08:15
                            [post_modified_gmt] => 2023-07-10 15:08:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [338] => WP_Post Object
                        (
                            [ID] => 3797
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:54:44
                            [post_date_gmt] => 2021-09-10 09:54:44
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:07:04
                            [post_modified_gmt] => 2023-07-10 15:07:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [339] => WP_Post Object
                        (
                            [ID] => 3796
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:03:43
                            [post_date_gmt] => 2021-09-10 09:03:43
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 10:54:33
                            [post_modified_gmt] => 2023-07-10 10:54:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [340] => WP_Post Object
                        (
                            [ID] => 3694
                            [post_author] => 5
                            [post_date] => 2021-08-18 09:56:18
                            [post_date_gmt] => 2021-08-18 09:56:18
                            [post_content] => 
                            [post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-19 15:42:35
                            [post_modified_gmt] => 2022-12-19 15:42:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3694
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [341] => WP_Post Object
                        (
                            [ID] => 3691
                            [post_author] => 5
                            [post_date] => 2021-08-18 09:29:08
                            [post_date_gmt] => 2021-08-18 09:29:08
                            [post_content] => 
                            [post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:48:43
                            [post_modified_gmt] => 2022-12-14 15:48:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3691
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [342] => WP_Post Object
                        (
                            [ID] => 3689
                            [post_author] => 5
                            [post_date] => 2021-08-18 09:13:21
                            [post_date_gmt] => 2021-08-18 09:13:21
                            [post_content] => 
                            [post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:30:10
                            [post_modified_gmt] => 2022-09-29 11:30:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3689
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [343] => WP_Post Object
                        (
                            [ID] => 3418
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:06:19
                            [post_date_gmt] => 2021-06-30 19:06:19
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-30 15:19:00
                            [post_modified_gmt] => 2023-08-30 15:19:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3418
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [344] => WP_Post Object
                        (
                            [ID] => 3416
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:02:19
                            [post_date_gmt] => 2021-06-30 19:02:19
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-30 15:15:44
                            [post_modified_gmt] => 2023-08-30 15:15:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3416
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [345] => WP_Post Object
                        (
                            [ID] => 3415
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:00:20
                            [post_date_gmt] => 2021-06-30 19:00:20
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-30 14:41:35
                            [post_modified_gmt] => 2023-08-30 14:41:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3415
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [346] => WP_Post Object
                        (
                            [ID] => 3414
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:54:43
                            [post_date_gmt] => 2021-06-30 18:54:43
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:41:52
                            [post_modified_gmt] => 2023-11-10 14:41:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3414
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [347] => WP_Post Object
                        (
                            [ID] => 3413
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:52:08
                            [post_date_gmt] => 2021-06-30 18:52:08
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 15:34:39
                            [post_modified_gmt] => 2023-08-29 15:34:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3413
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [348] => WP_Post Object
                        (
                            [ID] => 3412
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:48:13
                            [post_date_gmt] => 2021-06-30 18:48:13
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 14:25:19
                            [post_modified_gmt] => 2023-08-29 14:25:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3412
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [349] => WP_Post Object
                        (
                            [ID] => 3411
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:39:53
                            [post_date_gmt] => 2021-06-30 18:39:53
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 13:43:53
                            [post_modified_gmt] => 2023-08-29 13:43:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3411
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [350] => WP_Post Object
                        (
                            [ID] => 3410
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:37:02
                            [post_date_gmt] => 2021-06-30 18:37:02
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 13:21:03
                            [post_modified_gmt] => 2023-08-29 13:21:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3410
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [351] => WP_Post Object
                        (
                            [ID] => 3406
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:25:58
                            [post_date_gmt] => 2021-06-30 18:25:58
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 13:06:12
                            [post_modified_gmt] => 2023-08-29 13:06:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3406
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [352] => WP_Post Object
                        (
                            [ID] => 3379
                            [post_author] => 5
                            [post_date] => 2021-06-30 17:56:54
                            [post_date_gmt] => 2021-06-30 17:56:54
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:39:06
                            [post_modified_gmt] => 2022-10-12 13:39:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3379
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [353] => WP_Post Object
                        (
                            [ID] => 3378
                            [post_author] => 5
                            [post_date] => 2021-06-30 17:55:17
                            [post_date_gmt] => 2021-06-30 17:55:17
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-12 09:46:22
                            [post_modified_gmt] => 2023-04-12 09:46:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3378
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [354] => WP_Post Object
                        (
                            [ID] => 3377
                            [post_author] => 5
                            [post_date] => 2021-06-30 17:20:14
                            [post_date_gmt] => 2021-06-30 17:20:14
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:42:01
                            [post_modified_gmt] => 2022-09-26 14:42:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3377
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [355] => WP_Post Object
                        (
                            [ID] => 3376
                            [post_author] => 5
                            [post_date] => 2021-06-30 16:38:25
                            [post_date_gmt] => 2021-06-30 16:38:25
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:54:45
                            [post_modified_gmt] => 2022-08-11 09:54:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3376
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [356] => WP_Post Object
                        (
                            [ID] => 3375
                            [post_author] => 5
                            [post_date] => 2021-06-30 16:36:27
                            [post_date_gmt] => 2021-06-30 16:36:27
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-24 12:55:34
                            [post_modified_gmt] => 2023-11-24 12:55:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3375
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [357] => WP_Post Object
                        (
                            [ID] => 2426
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:02:08
                            [post_date_gmt] => 2020-12-14 15:02:08
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-20 14:38:47
                            [post_modified_gmt] => 2023-07-20 14:38:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [358] => WP_Post Object
                        (
                            [ID] => 2424
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:01:40
                            [post_date_gmt] => 2020-12-14 15:01:40
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:56:17
                            [post_modified_gmt] => 2023-05-04 11:56:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [359] => WP_Post Object
                        (
                            [ID] => 1315
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:56:03
                            [post_date_gmt] => 2020-05-23 17:56:03
                            [post_content] => 
                            [post_title] => MPP – ViiV, Dolutegravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:05:51
                            [post_modified_gmt] => 2022-09-29 12:05:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1315
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [360] => WP_Post Object
                        (
                            [ID] => 1313
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:55:00
                            [post_date_gmt] => 2020-05-23 17:55:00
                            [post_content] => 
                            [post_title] => AbbVie – MPP, HIV Antiretroviral Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:04:06
                            [post_modified_gmt] => 2023-09-18 12:04:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1313
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [361] => WP_Post Object
                        (
                            [ID] => 1314
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:54:57
                            [post_date_gmt] => 2020-05-23 17:54:57
                            [post_content] => 
                            [post_title] => BMS – MPP Sublicense & Tech Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:05:18
                            [post_modified_gmt] => 2023-09-18 12:05:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1314
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [362] => WP_Post Object
                        (
                            [ID] => 1287
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:05:30
                            [post_date_gmt] => 2020-05-22 23:05:30
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 08:08:26
                            [post_modified_gmt] => 2023-05-05 08:08:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [363] => WP_Post Object
                        (
                            [ID] => 1285
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:01:07
                            [post_date_gmt] => 2020-05-22 23:01:07
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:47:24
                            [post_modified_gmt] => 2023-01-04 15:47:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1285
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [364] => WP_Post Object
                        (
                            [ID] => 1272
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:36:39
                            [post_date_gmt] => 2020-05-22 22:36:39
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bu-startup-exclusive-license-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 13:24:05
                            [post_modified_gmt] => 2023-06-20 13:24:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1272
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [365] => WP_Post Object
                        (
                            [ID] => 1267
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:26:39
                            [post_date_gmt] => 2020-05-22 22:26:39
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:43:37
                            [post_modified_gmt] => 2022-09-29 11:43:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1267
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [366] => WP_Post Object
                        (
                            [ID] => 1264
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:22:55
                            [post_date_gmt] => 2020-05-22 22:22:55
                            [post_content] => 
                            [post_title] => Gilead – Indian Generic Manufacturers, HCV License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-06 13:18:47
                            [post_modified_gmt] => 2021-12-06 13:18:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1264
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [367] => WP_Post Object
                        (
                            [ID] => 1263
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:20:56
                            [post_date_gmt] => 2020-05-22 22:20:56
                            [post_content] => 
                            [post_title] => Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:30:35
                            [post_modified_gmt] => 2022-09-29 11:30:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1263
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [368] => WP_Post Object
                        (
                            [ID] => 1249
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:37:42
                            [post_date_gmt] => 2020-05-22 21:37:42
                            [post_content] => 
                            [post_title] => Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 15:42:56
                            [post_modified_gmt] => 2022-09-27 15:42:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1249
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [369] => WP_Post Object
                        (
                            [ID] => 1242
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:26:04
                            [post_date_gmt] => 2020-05-22 21:26:04
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 12:15:57
                            [post_modified_gmt] => 2022-10-13 12:15:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1242
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [370] => WP_Post Object
                        (
                            [ID] => 1235
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:01:14
                            [post_date_gmt] => 2020-05-22 21:01:14
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-19 15:49:24
                            [post_modified_gmt] => 2022-12-19 15:49:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1235
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [371] => WP_Post Object
                        (
                            [ID] => 1229
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:51:35
                            [post_date_gmt] => 2020-05-22 20:51:35
                            [post_content] => 
                            [post_title] => BMS – MPP – Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:04:47
                            [post_modified_gmt] => 2023-09-18 12:04:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1229
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [372] => WP_Post Object
                        (
                            [ID] => 1228
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:49:20
                            [post_date_gmt] => 2020-05-22 20:49:20
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 07:36:00
                            [post_modified_gmt] => 2022-09-29 07:36:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1228
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [373] => WP_Post Object
                        (
                            [ID] => 1207
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:42:36
                            [post_date_gmt] => 2020-05-22 19:42:36
                            [post_content] => 
                            [post_title] => Pfizer – MPP, Sutezolid License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-pfizer-re-sutezolid
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:40:39
                            [post_modified_gmt] => 2023-11-10 14:40:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1207
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [374] => WP_Post Object
                        (
                            [ID] => 1183
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:06:26
                            [post_date_gmt] => 2020-05-22 00:06:26
                            [post_content] => 
                            [post_title] => AbbVie – MPP, HIV Antiretroviral Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-abbvie
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:04:12
                            [post_modified_gmt] => 2023-09-18 12:04:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1183
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [375] => WP_Post Object
                        (
                            [ID] => 1168
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:26:48
                            [post_date_gmt] => 2020-05-21 23:26:48
                            [post_content] => 
                            [post_title] => NIH - Non-Profit, Model License Agreement Terms
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-model-license-agreement-for-use-by-non-profit-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 14:02:19
                            [post_modified_gmt] => 2023-08-11 14:02:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1168
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [376] => WP_Post Object
                        (
                            [ID] => 1145
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:48:08
                            [post_date_gmt] => 2020-05-21 22:48:08
                            [post_content] => 
                            [post_title] => Gilead – Indian Generic Manufacturers, HCV License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-10 12:27:49
                            [post_modified_gmt] => 2022-11-10 12:27:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1145
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [377] => WP_Post Object
                        (
                            [ID] => 1140
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:37:27
                            [post_date_gmt] => 2020-05-21 22:37:27
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 08:07:50
                            [post_modified_gmt] => 2023-05-05 08:07:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1140
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [378] => WP_Post Object
                        (
                            [ID] => 1135
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:19:46
                            [post_date_gmt] => 2020-05-21 22:19:46
                            [post_content] => 
                            [post_title] => NIH - Non-Profit, Model License Agreement Terms
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-model-license-agreement-for-use-by-non-profit
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 14:01:14
                            [post_modified_gmt] => 2023-08-11 14:01:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1135
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [379] => WP_Post Object
                        (
                            [ID] => 1127
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:47:49
                            [post_date_gmt] => 2020-05-21 21:47:49
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bu-startup-exclusive-license
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 13:11:18
                            [post_modified_gmt] => 2023-06-20 13:11:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1127
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [380] => WP_Post Object
                        (
                            [ID] => 1125
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:44:59
                            [post_date_gmt] => 2020-05-21 21:44:59
                            [post_content] => 
                            [post_title] => AbbVie – MPP, HIV Antiretroviral Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:32:46
                            [post_modified_gmt] => 2023-11-10 14:32:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1125
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [381] => WP_Post Object
                        (
                            [ID] => 1124
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:41:21
                            [post_date_gmt] => 2020-05-21 21:41:21
                            [post_content] => 
                            [post_title] => BMS – MPP Sublicense & Tech Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:05:24
                            [post_modified_gmt] => 2023-09-18 12:05:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1124
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [382] => WP_Post Object
                        (
                            [ID] => 1123
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:37:52
                            [post_date_gmt] => 2020-05-21 21:37:52
                            [post_content] => 
                            [post_title] => MPP – ViiV, Dolutegravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-10 12:30:27
                            [post_modified_gmt] => 2022-11-10 12:30:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [383] => WP_Post Object
                        (
                            [ID] => 1122
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:30:19
                            [post_date_gmt] => 2020-05-21 21:30:19
                            [post_content] => 
                            [post_title] => BMS – MPP – Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:38:26
                            [post_modified_gmt] => 2023-11-10 14:38:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [384] => WP_Post Object
                        (
                            [ID] => 1118
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:24:00
                            [post_date_gmt] => 2020-05-21 21:24:00
                            [post_content] => 
                            [post_title] => AbbVie – MPP, HIV Antiretroviral License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpps-license-agreement-with-abbvie
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:03:56
                            [post_modified_gmt] => 2023-09-18 12:03:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1118
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [385] => WP_Post Object
                        (
                            [ID] => 1117
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:17:31
                            [post_date_gmt] => 2020-05-21 21:17:31
                            [post_content] => 
                            [post_title] => University of Liverpool – MPP, Solid Drug Nanoparticle Technology License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpps-license-agreement-with-university-of-liverpool
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 12:06:52
                            [post_modified_gmt] => 2023-09-18 12:06:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1117
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [386] => WP_Post Object
                        (
                            [ID] => 1114
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:13:15
                            [post_date_gmt] => 2020-05-21 21:13:15
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:30:53
                            [post_modified_gmt] => 2023-05-04 11:30:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1114
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [387] => WP_Post Object
                        (
                            [ID] => 1112
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:06:05
                            [post_date_gmt] => 2020-05-21 21:06:05
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 10:00:24
                            [post_modified_gmt] => 2022-07-13 10:00:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1112
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 388
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 11483
                    [post_author] => 5
                    [post_date] => 2023-11-20 09:38:10
                    [post_date_gmt] => 2023-11-20 09:38:10
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:40:42
                    [post_modified_gmt] => 2023-11-20 09:40:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11483
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 388
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 777c6aaed20163dd62f109b4f1dfb112
            [query_vars_changed:WP_Query:private] => 
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => 
            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_agreement_q_rslts] => 
    [text_provision_q_rslts] => 
    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 11483
                    [post_author] => 5
                    [post_date] => 2023-11-20 09:38:10
                    [post_date_gmt] => 2023-11-20 09:38:10
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:40:42
                    [post_modified_gmt] => 2023-11-20 09:40:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11483
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 11482
                    [post_author] => 5
                    [post_date] => 2023-11-20 09:34:04
                    [post_date_gmt] => 2023-11-20 09:34:04
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:34:04
                    [post_modified_gmt] => 2023-11-20 09:34:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11482
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 11481
                    [post_author] => 5
                    [post_date] => 2023-11-20 09:32:40
                    [post_date_gmt] => 2023-11-20 09:32:40
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:32:40
                    [post_modified_gmt] => 2023-11-20 09:32:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11481
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 11480
                    [post_author] => 5
                    [post_date] => 2023-11-20 09:24:22
                    [post_date_gmt] => 2023-11-20 09:24:22
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:31:52
                    [post_modified_gmt] => 2023-11-20 09:31:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11480
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 11479
                    [post_author] => 5
                    [post_date] => 2023-11-20 09:20:32
                    [post_date_gmt] => 2023-11-20 09:20:32
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:20:32
                    [post_modified_gmt] => 2023-11-20 09:20:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11479
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 11478
                    [post_author] => 5
                    [post_date] => 2023-11-20 09:18:25
                    [post_date_gmt] => 2023-11-20 09:18:25
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:18:25
                    [post_modified_gmt] => 2023-11-20 09:18:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11478
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 11477
                    [post_author] => 5
                    [post_date] => 2023-11-20 09:10:11
                    [post_date_gmt] => 2023-11-20 09:10:11
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:19:50
                    [post_modified_gmt] => 2023-11-20 09:19:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11477
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 11476
                    [post_author] => 5
                    [post_date] => 2023-11-20 08:57:12
                    [post_date_gmt] => 2023-11-20 08:57:12
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:18:05
                    [post_modified_gmt] => 2023-11-20 09:18:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11476
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 11474
                    [post_author] => 5
                    [post_date] => 2023-11-20 08:54:04
                    [post_date_gmt] => 2023-11-20 08:54:04
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 08:54:04
                    [post_modified_gmt] => 2023-11-20 08:54:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11474
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 11473
                    [post_author] => 5
                    [post_date] => 2023-11-20 08:50:29
                    [post_date_gmt] => 2023-11-20 08:50:29
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 08:51:41
                    [post_modified_gmt] => 2023-11-20 08:51:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11473
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 11472
                    [post_author] => 5
                    [post_date] => 2023-11-20 08:48:59
                    [post_date_gmt] => 2023-11-20 08:48:59
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:01:24
                    [post_modified_gmt] => 2023-11-20 09:01:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11472
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 11467
                    [post_author] => 5
                    [post_date] => 2023-11-20 08:46:09
                    [post_date_gmt] => 2023-11-20 08:46:09
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 08:46:09
                    [post_modified_gmt] => 2023-11-20 08:46:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 11471
                    [post_author] => 5
                    [post_date] => 2023-11-20 08:40:37
                    [post_date_gmt] => 2023-11-20 08:40:37
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 08:41:18
                    [post_modified_gmt] => 2023-11-20 08:41:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11471
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 11470
                    [post_author] => 5
                    [post_date] => 2023-11-20 08:39:41
                    [post_date_gmt] => 2023-11-20 08:39:41
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 08:39:41
                    [post_modified_gmt] => 2023-11-20 08:39:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11470
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 11468
                    [post_author] => 5
                    [post_date] => 2023-11-20 08:37:54
                    [post_date_gmt] => 2023-11-20 08:37:54
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:25:50
                    [post_modified_gmt] => 2023-11-20 09:25:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11468
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 11485
                    [post_author] => 5
                    [post_date] => 2023-11-20 08:32:36
                    [post_date_gmt] => 2023-11-20 08:32:36
                    [post_content] => 
                    [post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 09:40:15
                    [post_modified_gmt] => 2023-11-20 09:40:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11485
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 11361
                    [post_author] => 5
                    [post_date] => 2023-10-11 15:17:51
                    [post_date_gmt] => 2023-10-11 15:17:51
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 16:01:11
                    [post_modified_gmt] => 2023-10-11 16:01:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11361
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 11360
                    [post_author] => 5
                    [post_date] => 2023-10-11 15:03:54
                    [post_date_gmt] => 2023-10-11 15:03:54
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 16:02:40
                    [post_modified_gmt] => 2023-10-11 16:02:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11360
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 11359
                    [post_author] => 5
                    [post_date] => 2023-10-11 14:14:13
                    [post_date_gmt] => 2023-10-11 14:14:13
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 16:00:13
                    [post_modified_gmt] => 2023-10-11 16:00:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11359
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 11358
                    [post_author] => 5
                    [post_date] => 2023-10-11 13:57:27
                    [post_date_gmt] => 2023-10-11 13:57:27
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:59:35
                    [post_modified_gmt] => 2023-10-11 15:59:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11358
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 11357
                    [post_author] => 5
                    [post_date] => 2023-10-11 13:42:17
                    [post_date_gmt] => 2023-10-11 13:42:17
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:59:14
                    [post_modified_gmt] => 2023-10-11 15:59:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11357
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 11356
                    [post_author] => 5
                    [post_date] => 2023-10-11 13:32:54
                    [post_date_gmt] => 2023-10-11 13:32:54
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:51:52
                    [post_modified_gmt] => 2023-10-11 15:51:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11356
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 11354
                    [post_author] => 5
                    [post_date] => 2023-10-11 12:48:35
                    [post_date_gmt] => 2023-10-11 12:48:35
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:52:44
                    [post_modified_gmt] => 2023-10-11 15:52:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11354
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 11353
                    [post_author] => 5
                    [post_date] => 2023-10-11 12:44:32
                    [post_date_gmt] => 2023-10-11 12:44:32
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:53:24
                    [post_modified_gmt] => 2023-10-11 15:53:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11353
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 11351
                    [post_author] => 5
                    [post_date] => 2023-10-11 12:30:03
                    [post_date_gmt] => 2023-10-11 12:30:03
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:56:38
                    [post_modified_gmt] => 2023-10-11 15:56:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11351
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 11350
                    [post_author] => 5
                    [post_date] => 2023-10-10 14:05:08
                    [post_date_gmt] => 2023-10-10 14:05:08
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:54:46
                    [post_modified_gmt] => 2023-10-11 15:54:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11350
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 11349
                    [post_author] => 5
                    [post_date] => 2023-10-10 13:26:39
                    [post_date_gmt] => 2023-10-10 13:26:39
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:54:08
                    [post_modified_gmt] => 2023-10-11 15:54:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11349
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 11347
                    [post_author] => 5
                    [post_date] => 2023-10-10 13:10:51
                    [post_date_gmt] => 2023-10-10 13:10:51
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:58:36
                    [post_modified_gmt] => 2023-10-11 15:58:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11347
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 11348
                    [post_author] => 5
                    [post_date] => 2023-10-10 12:20:52
                    [post_date_gmt] => 2023-10-10 12:20:52
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:52:12
                    [post_modified_gmt] => 2023-10-11 15:52:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11348
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 11346
                    [post_author] => 5
                    [post_date] => 2023-10-10 11:44:01
                    [post_date_gmt] => 2023-10-10 11:44:01
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:50:28
                    [post_modified_gmt] => 2023-10-11 15:50:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11346
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 11345
                    [post_author] => 5
                    [post_date] => 2023-10-10 09:45:26
                    [post_date_gmt] => 2023-10-10 09:45:26
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:57:28
                    [post_modified_gmt] => 2023-10-11 15:57:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11345
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 11337
                    [post_author] => 5
                    [post_date] => 2023-09-26 13:37:20
                    [post_date_gmt] => 2023-09-26 13:37:20
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:20:14
                    [post_modified_gmt] => 2023-09-27 09:20:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11337
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 11336
                    [post_author] => 5
                    [post_date] => 2023-09-26 12:26:24
                    [post_date_gmt] => 2023-09-26 12:26:24
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:19:55
                    [post_modified_gmt] => 2023-09-27 09:19:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11336
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 11335
                    [post_author] => 5
                    [post_date] => 2023-09-26 12:23:27
                    [post_date_gmt] => 2023-09-26 12:23:27
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:19:29
                    [post_modified_gmt] => 2023-09-27 09:19:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11335
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 11334
                    [post_author] => 5
                    [post_date] => 2023-09-26 12:20:43
                    [post_date_gmt] => 2023-09-26 12:20:43
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:17:25
                    [post_modified_gmt] => 2023-09-27 09:17:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11334
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 11333
                    [post_author] => 5
                    [post_date] => 2023-09-26 10:31:42
                    [post_date_gmt] => 2023-09-26 10:31:42
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:17:46
                    [post_modified_gmt] => 2023-09-27 09:17:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11333
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 11331
                    [post_author] => 5
                    [post_date] => 2023-09-26 10:25:29
                    [post_date_gmt] => 2023-09-26 10:25:29
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:18:47
                    [post_modified_gmt] => 2023-09-27 09:18:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11331
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 11330
                    [post_author] => 5
                    [post_date] => 2023-09-25 16:33:25
                    [post_date_gmt] => 2023-09-25 16:33:25
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:18:26
                    [post_modified_gmt] => 2023-09-27 09:18:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11330
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 11329
                    [post_author] => 5
                    [post_date] => 2023-09-25 16:31:48
                    [post_date_gmt] => 2023-09-25 16:31:48
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:18:04
                    [post_modified_gmt] => 2023-09-27 09:18:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11329
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 11328
                    [post_author] => 5
                    [post_date] => 2023-09-25 16:22:13
                    [post_date_gmt] => 2023-09-25 16:22:13
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:16:55
                    [post_modified_gmt] => 2023-09-27 09:16:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11328
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 11327
                    [post_author] => 5
                    [post_date] => 2023-09-25 16:20:19
                    [post_date_gmt] => 2023-09-25 16:20:19
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:19:08
                    [post_modified_gmt] => 2023-09-27 09:19:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11327
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 11260
                    [post_author] => 5
                    [post_date] => 2023-09-18 11:51:39
                    [post_date_gmt] => 2023-09-18 11:51:39
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 11:51:39
                    [post_modified_gmt] => 2023-09-18 11:51:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11260
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 11259
                    [post_author] => 5
                    [post_date] => 2023-09-18 11:17:07
                    [post_date_gmt] => 2023-09-18 11:17:07
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 11:17:07
                    [post_modified_gmt] => 2023-09-18 11:17:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11259
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 11258
                    [post_author] => 5
                    [post_date] => 2023-09-18 11:14:03
                    [post_date_gmt] => 2023-09-18 11:14:03
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 11:14:03
                    [post_modified_gmt] => 2023-09-18 11:14:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11258
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [44] => WP_Post Object
                (
                    [ID] => 11257
                    [post_author] => 5
                    [post_date] => 2023-09-18 10:52:07
                    [post_date_gmt] => 2023-09-18 10:52:07
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 11:52:21
                    [post_modified_gmt] => 2023-09-18 11:52:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11257
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [45] => WP_Post Object
                (
                    [ID] => 11256
                    [post_author] => 5
                    [post_date] => 2023-09-18 10:42:58
                    [post_date_gmt] => 2023-09-18 10:42:58
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 10:42:58
                    [post_modified_gmt] => 2023-09-18 10:42:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11256
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [46] => WP_Post Object
                (
                    [ID] => 11255
                    [post_author] => 5
                    [post_date] => 2023-09-18 10:36:46
                    [post_date_gmt] => 2023-09-18 10:36:46
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 10:37:13
                    [post_modified_gmt] => 2023-09-18 10:37:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11255
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [47] => WP_Post Object
                (
                    [ID] => 11254
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:49:03
                    [post_date_gmt] => 2023-09-18 09:49:03
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:49:03
                    [post_modified_gmt] => 2023-09-18 09:49:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11254
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [48] => WP_Post Object
                (
                    [ID] => 11252
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:45:34
                    [post_date_gmt] => 2023-09-18 09:45:34
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:45:34
                    [post_modified_gmt] => 2023-09-18 09:45:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11252
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [49] => WP_Post Object
                (
                    [ID] => 11251
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:38:14
                    [post_date_gmt] => 2023-09-18 09:38:14
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:38:14
                    [post_modified_gmt] => 2023-09-18 09:38:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11251
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [50] => WP_Post Object
                (
                    [ID] => 11250
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:35:19
                    [post_date_gmt] => 2023-09-18 09:35:19
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:35:19
                    [post_modified_gmt] => 2023-09-18 09:35:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11250
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [51] => WP_Post Object
                (
                    [ID] => 11248
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:31:07
                    [post_date_gmt] => 2023-09-18 09:31:07
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:31:07
                    [post_modified_gmt] => 2023-09-18 09:31:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11248
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [52] => WP_Post Object
                (
                    [ID] => 11247
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:17:13
                    [post_date_gmt] => 2023-09-18 09:17:13
                    [post_content] => 
                    [post_title] => CSIC - MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:32:09
                    [post_modified_gmt] => 2023-09-18 09:32:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11247
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [53] => WP_Post Object
                (
                    [ID] => 11134
                    [post_author] => 5
                    [post_date] => 2023-09-04 13:43:48
                    [post_date_gmt] => 2023-09-04 13:43:48
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:43:48
                    [post_modified_gmt] => 2023-09-04 13:43:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11134
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [54] => WP_Post Object
                (
                    [ID] => 11133
                    [post_author] => 5
                    [post_date] => 2023-09-04 13:30:07
                    [post_date_gmt] => 2023-09-04 13:30:07
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:44:48
                    [post_modified_gmt] => 2023-09-04 13:44:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11133
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [55] => WP_Post Object
                (
                    [ID] => 11132
                    [post_author] => 5
                    [post_date] => 2023-09-04 13:10:26
                    [post_date_gmt] => 2023-09-04 13:10:26
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:10:26
                    [post_modified_gmt] => 2023-09-04 13:10:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11132
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [56] => WP_Post Object
                (
                    [ID] => 11131
                    [post_author] => 5
                    [post_date] => 2023-09-04 13:07:25
                    [post_date_gmt] => 2023-09-04 13:07:25
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:07:25
                    [post_modified_gmt] => 2023-09-04 13:07:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11131
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [57] => WP_Post Object
                (
                    [ID] => 11130
                    [post_author] => 5
                    [post_date] => 2023-09-04 13:04:47
                    [post_date_gmt] => 2023-09-04 13:04:47
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:04:47
                    [post_modified_gmt] => 2023-09-04 13:04:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11130
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [58] => WP_Post Object
                (
                    [ID] => 11129
                    [post_author] => 5
                    [post_date] => 2023-09-04 12:53:59
                    [post_date_gmt] => 2023-09-04 12:53:59
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:42:57
                    [post_modified_gmt] => 2023-11-10 14:42:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11129
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [59] => WP_Post Object
                (
                    [ID] => 11128
                    [post_author] => 5
                    [post_date] => 2023-09-04 12:35:39
                    [post_date_gmt] => 2023-09-04 12:35:39
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 12:36:50
                    [post_modified_gmt] => 2023-09-04 12:36:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11128
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [60] => WP_Post Object
                (
                    [ID] => 11127
                    [post_author] => 5
                    [post_date] => 2023-09-04 12:07:04
                    [post_date_gmt] => 2023-09-04 12:07:04
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 12:22:43
                    [post_modified_gmt] => 2023-09-04 12:22:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11127
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [61] => WP_Post Object
                (
                    [ID] => 11126
                    [post_author] => 5
                    [post_date] => 2023-09-04 11:45:05
                    [post_date_gmt] => 2023-09-04 11:45:05
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:40:47
                    [post_modified_gmt] => 2023-09-04 13:40:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11126
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [62] => WP_Post Object
                (
                    [ID] => 11125
                    [post_author] => 5
                    [post_date] => 2023-09-04 11:24:43
                    [post_date_gmt] => 2023-09-04 11:24:43
                    [post_content] => 
                    [post_title] => NIH - UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:38:26
                    [post_modified_gmt] => 2023-09-04 13:38:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11125
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [63] => WP_Post Object
                (
                    [ID] => 11124
                    [post_author] => 5
                    [post_date] => 2023-09-04 10:26:26
                    [post_date_gmt] => 2023-09-04 10:26:26
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 10:26:26
                    [post_modified_gmt] => 2023-09-04 10:26:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11124
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [64] => WP_Post Object
                (
                    [ID] => 11123
                    [post_author] => 5
                    [post_date] => 2023-09-04 10:23:35
                    [post_date_gmt] => 2023-09-04 10:23:35
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:45:31
                    [post_modified_gmt] => 2023-09-04 13:45:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11123
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [65] => WP_Post Object
                (
                    [ID] => 11118
                    [post_author] => 5
                    [post_date] => 2023-09-04 09:54:48
                    [post_date_gmt] => 2023-09-04 09:54:48
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 09:55:20
                    [post_modified_gmt] => 2023-09-04 09:55:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11118
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [66] => WP_Post Object
                (
                    [ID] => 11116
                    [post_author] => 5
                    [post_date] => 2023-09-01 12:33:27
                    [post_date_gmt] => 2023-09-01 12:33:27
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-20 12:51:48
                    [post_modified_gmt] => 2023-11-20 12:51:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11116
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [67] => WP_Post Object
                (
                    [ID] => 11114
                    [post_author] => 5
                    [post_date] => 2023-09-01 12:30:00
                    [post_date_gmt] => 2023-09-01 12:30:00
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-01 12:41:24
                    [post_modified_gmt] => 2023-09-01 12:41:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11114
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [68] => WP_Post Object
                (
                    [ID] => 11113
                    [post_author] => 5
                    [post_date] => 2023-09-01 12:26:23
                    [post_date_gmt] => 2023-09-01 12:26:23
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:58:18
                    [post_modified_gmt] => 2023-11-10 14:58:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11113
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [69] => WP_Post Object
                (
                    [ID] => 11107
                    [post_author] => 5
                    [post_date] => 2023-08-31 14:53:13
                    [post_date_gmt] => 2023-08-31 14:53:13
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 12:08:07
                    [post_modified_gmt] => 2023-09-04 12:08:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11107
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [70] => WP_Post Object
                (
                    [ID] => 11106
                    [post_author] => 5
                    [post_date] => 2023-08-31 12:52:01
                    [post_date_gmt] => 2023-08-31 12:52:01
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-01 12:42:49
                    [post_modified_gmt] => 2023-09-01 12:42:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11106
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [71] => WP_Post Object
                (
                    [ID] => 11105
                    [post_author] => 5
                    [post_date] => 2023-08-31 12:50:06
                    [post_date_gmt] => 2023-08-31 12:50:06
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-01 12:43:07
                    [post_modified_gmt] => 2023-09-01 12:43:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11105
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [72] => WP_Post Object
                (
                    [ID] => 11104
                    [post_author] => 5
                    [post_date] => 2023-08-31 11:48:00
                    [post_date_gmt] => 2023-08-31 11:48:00
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-01 12:43:25
                    [post_modified_gmt] => 2023-09-01 12:43:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11104
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [73] => WP_Post Object
                (
                    [ID] => 11103
                    [post_author] => 5
                    [post_date] => 2023-08-31 11:41:15
                    [post_date_gmt] => 2023-08-31 11:41:15
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-01 12:45:05
                    [post_modified_gmt] => 2023-09-01 12:45:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11103
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [74] => WP_Post Object
                (
                    [ID] => 11102
                    [post_author] => 5
                    [post_date] => 2023-08-31 11:25:29
                    [post_date_gmt] => 2023-08-31 11:25:29
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-01 12:45:30
                    [post_modified_gmt] => 2023-09-01 12:45:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11102
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [75] => WP_Post Object
                (
                    [ID] => 11101
                    [post_author] => 5
                    [post_date] => 2023-08-31 11:04:44
                    [post_date_gmt] => 2023-08-31 11:04:44
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-01 12:45:47
                    [post_modified_gmt] => 2023-09-01 12:45:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11101
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [76] => WP_Post Object
                (
                    [ID] => 11097
                    [post_author] => 5
                    [post_date] => 2023-08-31 10:10:17
                    [post_date_gmt] => 2023-08-31 10:10:17
                    [post_content] => 
                    [post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 12:21:34
                    [post_modified_gmt] => 2023-09-04 12:21:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11097
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [77] => WP_Post Object
                (
                    [ID] => 11096
                    [post_author] => 5
                    [post_date] => 2023-08-31 09:33:42
                    [post_date_gmt] => 2023-08-31 09:33:42
                    [post_content] => 
                    [post_title] => NIH - UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-31 10:11:08
                    [post_modified_gmt] => 2023-08-31 10:11:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11096
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [78] => WP_Post Object
                (
                    [ID] => 11093
                    [post_author] => 5
                    [post_date] => 2023-08-30 15:21:05
                    [post_date_gmt] => 2023-08-30 15:21:05
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-30 15:21:05
                    [post_modified_gmt] => 2023-08-30 15:21:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11093
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [79] => WP_Post Object
                (
                    [ID] => 11092
                    [post_author] => 5
                    [post_date] => 2023-08-30 15:15:53
                    [post_date_gmt] => 2023-08-30 15:15:53
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:46:13
                    [post_modified_gmt] => 2023-09-04 13:46:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11092
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [80] => WP_Post Object
                (
                    [ID] => 11091
                    [post_author] => 5
                    [post_date] => 2023-08-30 14:56:10
                    [post_date_gmt] => 2023-08-30 14:56:10
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 09:55:32
                    [post_modified_gmt] => 2023-09-04 09:55:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11091
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [81] => WP_Post Object
                (
                    [ID] => 11090
                    [post_author] => 5
                    [post_date] => 2023-08-30 14:52:31
                    [post_date_gmt] => 2023-08-30 14:52:31
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-30 14:52:31
                    [post_modified_gmt] => 2023-08-30 14:52:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11090
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [82] => WP_Post Object
                (
                    [ID] => 11089
                    [post_author] => 5
                    [post_date] => 2023-08-30 14:38:46
                    [post_date_gmt] => 2023-08-30 14:38:46
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-30 14:38:46
                    [post_modified_gmt] => 2023-08-30 14:38:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11089
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [83] => WP_Post Object
                (
                    [ID] => 11088
                    [post_author] => 5
                    [post_date] => 2023-08-30 14:31:40
                    [post_date_gmt] => 2023-08-30 14:31:40
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:58:36
                    [post_modified_gmt] => 2023-11-10 14:58:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11088
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [84] => WP_Post Object
                (
                    [ID] => 11087
                    [post_author] => 5
                    [post_date] => 2023-08-29 15:34:57
                    [post_date_gmt] => 2023-08-29 15:34:57
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 11087
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 12:07:36
                    [post_modified_gmt] => 2023-09-04 12:07:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11087
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [85] => WP_Post Object
                (
                    [ID] => 11086
                    [post_author] => 5
                    [post_date] => 2023-08-29 14:25:37
                    [post_date_gmt] => 2023-08-29 14:25:37
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-31 12:57:48
                    [post_modified_gmt] => 2023-08-31 12:57:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11086
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [86] => WP_Post Object
                (
                    [ID] => 11085
                    [post_author] => 5
                    [post_date] => 2023-08-29 13:58:20
                    [post_date_gmt] => 2023-08-29 13:58:20
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 13:58:20
                    [post_modified_gmt] => 2023-08-29 13:58:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11085
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [87] => WP_Post Object
                (
                    [ID] => 11084
                    [post_author] => 5
                    [post_date] => 2023-08-29 13:34:09
                    [post_date_gmt] => 2023-08-29 13:34:09
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 13:58:43
                    [post_modified_gmt] => 2023-08-29 13:58:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11084
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [88] => WP_Post Object
                (
                    [ID] => 11083
                    [post_author] => 5
                    [post_date] => 2023-08-29 13:04:02
                    [post_date_gmt] => 2023-08-29 13:04:02
                    [post_content] => 
                    [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 13:04:02
                    [post_modified_gmt] => 2023-08-29 13:04:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11083
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [89] => WP_Post Object
                (
                    [ID] => 11082
                    [post_author] => 5
                    [post_date] => 2023-08-29 13:00:36
                    [post_date_gmt] => 2023-08-29 13:00:36
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 13:00:36
                    [post_modified_gmt] => 2023-08-29 13:00:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11082
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [90] => WP_Post Object
                (
                    [ID] => 11081
                    [post_author] => 5
                    [post_date] => 2023-08-29 12:46:57
                    [post_date_gmt] => 2023-08-29 12:46:57
                    [post_content] => 
                    [post_title] => PHS (NIH/CDC/FDA), Model Non-Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-nih-cdc-fda-model-non-exclusive-patent-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 12:46:57
                    [post_modified_gmt] => 2023-08-29 12:46:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11081
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [91] => WP_Post Object
                (
                    [ID] => 11078
                    [post_author] => 5
                    [post_date] => 2023-08-29 08:34:35
                    [post_date_gmt] => 2023-08-29 08:34:35
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 08:34:35
                    [post_modified_gmt] => 2023-08-29 08:34:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11078
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [92] => WP_Post Object
                (
                    [ID] => 11077
                    [post_author] => 5
                    [post_date] => 2023-08-29 08:31:51
                    [post_date_gmt] => 2023-08-29 08:31:51
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:52:03
                    [post_modified_gmt] => 2023-09-04 13:52:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11077
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [93] => WP_Post Object
                (
                    [ID] => 11076
                    [post_author] => 5
                    [post_date] => 2023-08-29 07:51:48
                    [post_date_gmt] => 2023-08-29 07:51:48
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 07:51:48
                    [post_modified_gmt] => 2023-08-29 07:51:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11076
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [94] => WP_Post Object
                (
                    [ID] => 11075
                    [post_author] => 5
                    [post_date] => 2023-08-29 07:22:26
                    [post_date_gmt] => 2023-08-29 07:22:26
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 07:23:23
                    [post_modified_gmt] => 2023-08-29 07:23:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11075
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [95] => WP_Post Object
                (
                    [ID] => 11074
                    [post_author] => 5
                    [post_date] => 2023-08-29 07:10:44
                    [post_date_gmt] => 2023-08-29 07:10:44
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:57:50
                    [post_modified_gmt] => 2023-11-10 14:57:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11074
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [96] => WP_Post Object
                (
                    [ID] => 11073
                    [post_author] => 5
                    [post_date] => 2023-08-28 17:57:35
                    [post_date_gmt] => 2023-08-28 17:57:35
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 17:58:29
                    [post_modified_gmt] => 2023-08-28 17:58:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11073
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [97] => WP_Post Object
                (
                    [ID] => 11072
                    [post_author] => 5
                    [post_date] => 2023-08-28 17:50:37
                    [post_date_gmt] => 2023-08-28 17:50:37
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 17:50:37
                    [post_modified_gmt] => 2023-08-28 17:50:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11072
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [98] => WP_Post Object
                (
                    [ID] => 11071
                    [post_author] => 5
                    [post_date] => 2023-08-28 12:56:19
                    [post_date_gmt] => 2023-08-28 12:56:19
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 13:22:48
                    [post_modified_gmt] => 2023-08-29 13:22:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11071
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [99] => WP_Post Object
                (
                    [ID] => 11070
                    [post_author] => 5
                    [post_date] => 2023-08-28 12:29:24
                    [post_date_gmt] => 2023-08-28 12:29:24
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 12:29:24
                    [post_modified_gmt] => 2023-08-28 12:29:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11070
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [100] => WP_Post Object
                (
                    [ID] => 11069
                    [post_author] => 5
                    [post_date] => 2023-08-28 12:24:54
                    [post_date_gmt] => 2023-08-28 12:24:54
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 12:24:54
                    [post_modified_gmt] => 2023-08-28 12:24:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11069
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [101] => WP_Post Object
                (
                    [ID] => 11068
                    [post_author] => 5
                    [post_date] => 2023-08-28 11:48:12
                    [post_date_gmt] => 2023-08-28 11:48:12
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 08:36:23
                    [post_modified_gmt] => 2023-08-29 08:36:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11068
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [102] => WP_Post Object
                (
                    [ID] => 11067
                    [post_author] => 5
                    [post_date] => 2023-08-28 11:10:31
                    [post_date_gmt] => 2023-08-28 11:10:31
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 08:38:45
                    [post_modified_gmt] => 2023-08-29 08:38:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11067
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [103] => WP_Post Object
                (
                    [ID] => 11065
                    [post_author] => 5
                    [post_date] => 2023-08-28 10:57:09
                    [post_date_gmt] => 2023-08-28 10:57:09
                    [post_content] => 
                    [post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:48:45
                    [post_modified_gmt] => 2023-09-04 13:48:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11065
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [104] => WP_Post Object
                (
                    [ID] => 11062
                    [post_author] => 5
                    [post_date] => 2023-08-25 09:33:29
                    [post_date_gmt] => 2023-08-25 09:33:29
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 08:17:36
                    [post_modified_gmt] => 2023-08-28 08:17:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11062
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [105] => WP_Post Object
                (
                    [ID] => 11045
                    [post_author] => 5
                    [post_date] => 2023-08-25 09:19:42
                    [post_date_gmt] => 2023-08-25 09:19:42
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:41:23
                    [post_modified_gmt] => 2023-11-10 14:41:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11045
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [106] => WP_Post Object
                (
                    [ID] => 11053
                    [post_author] => 5
                    [post_date] => 2023-08-25 09:07:42
                    [post_date_gmt] => 2023-08-25 09:07:42
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 07:22:15
                    [post_modified_gmt] => 2023-08-29 07:22:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11053
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [107] => WP_Post Object
                (
                    [ID] => 11061
                    [post_author] => 5
                    [post_date] => 2023-08-25 08:44:53
                    [post_date_gmt] => 2023-08-25 08:44:53
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 08:18:03
                    [post_modified_gmt] => 2023-08-28 08:18:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11061
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [108] => WP_Post Object
                (
                    [ID] => 11057
                    [post_author] => 5
                    [post_date] => 2023-08-25 08:38:20
                    [post_date_gmt] => 2023-08-25 08:38:20
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 17:55:13
                    [post_modified_gmt] => 2023-08-28 17:55:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11057
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [109] => WP_Post Object
                (
                    [ID] => 11059
                    [post_author] => 5
                    [post_date] => 2023-08-25 07:54:12
                    [post_date_gmt] => 2023-08-25 07:54:12
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 08:29:41
                    [post_modified_gmt] => 2023-08-29 08:29:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11059
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [110] => WP_Post Object
                (
                    [ID] => 11060
                    [post_author] => 5
                    [post_date] => 2023-08-25 07:36:19
                    [post_date_gmt] => 2023-08-25 07:36:19
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 11:33:07
                    [post_modified_gmt] => 2023-08-28 11:33:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11060
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [111] => WP_Post Object
                (
                    [ID] => 11058
                    [post_author] => 5
                    [post_date] => 2023-08-25 06:41:12
                    [post_date_gmt] => 2023-08-25 06:41:12
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-29 07:37:53
                    [post_modified_gmt] => 2023-08-29 07:37:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11058
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [112] => WP_Post Object
                (
                    [ID] => 11044
                    [post_author] => 5
                    [post_date] => 2023-08-24 15:28:36
                    [post_date_gmt] => 2023-08-24 15:28:36
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 08:18:43
                    [post_modified_gmt] => 2023-08-28 08:18:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11044
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [113] => WP_Post Object
                (
                    [ID] => 11056
                    [post_author] => 5
                    [post_date] => 2023-08-24 14:52:21
                    [post_date_gmt] => 2023-08-24 14:52:21
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 08:18:49
                    [post_modified_gmt] => 2023-08-28 08:18:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11056
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [114] => WP_Post Object
                (
                    [ID] => 11055
                    [post_author] => 5
                    [post_date] => 2023-08-24 14:04:36
                    [post_date_gmt] => 2023-08-24 14:04:36
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 08:18:54
                    [post_modified_gmt] => 2023-08-28 08:18:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11055
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [115] => WP_Post Object
                (
                    [ID] => 11054
                    [post_author] => 5
                    [post_date] => 2023-08-24 13:49:48
                    [post_date_gmt] => 2023-08-24 13:49:48
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 08:19:00
                    [post_modified_gmt] => 2023-08-28 08:19:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11054
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [116] => WP_Post Object
                (
                    [ID] => 11040
                    [post_author] => 5
                    [post_date] => 2023-08-24 12:12:13
                    [post_date_gmt] => 2023-08-24 12:12:13
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-04 13:53:13
                    [post_modified_gmt] => 2023-09-04 13:53:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11040
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [117] => WP_Post Object
                (
                    [ID] => 11043
                    [post_author] => 5
                    [post_date] => 2023-08-24 11:33:31
                    [post_date_gmt] => 2023-08-24 11:33:31
                    [post_content] => 
                    [post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-28 08:19:12
                    [post_modified_gmt] => 2023-08-28 08:19:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11043
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [118] => WP_Post Object
                (
                    [ID] => 11005
                    [post_author] => 5
                    [post_date] => 2023-08-11 14:24:06
                    [post_date_gmt] => 2023-08-11 14:24:06
                    [post_content] => 
                    [post_title] => NIH - Non-Profit, Model License Agreement Terms
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-non-profit-model-license-agreement-terms-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-11 14:24:06
                    [post_modified_gmt] => 2023-08-11 14:24:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11005
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [119] => WP_Post Object
                (
                    [ID] => 11004
                    [post_author] => 5
                    [post_date] => 2023-08-11 14:17:46
                    [post_date_gmt] => 2023-08-11 14:17:46
                    [post_content] => 
                    [post_title] => NIH - Non-Profit, Model License Agreement Terms
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-non-profit-model-license-agreement-terms-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-11 14:17:46
                    [post_modified_gmt] => 2023-08-11 14:17:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11004
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [120] => WP_Post Object
                (
                    [ID] => 11002
                    [post_author] => 5
                    [post_date] => 2023-08-11 14:04:44
                    [post_date_gmt] => 2023-08-11 14:04:44
                    [post_content] => 
                    [post_title] => NIH - Non-Profit, Model License Agreement Terms
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 11002
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-11 14:07:47
                    [post_modified_gmt] => 2023-08-11 14:07:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11002
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [121] => WP_Post Object
                (
                    [ID] => 11000
                    [post_author] => 5
                    [post_date] => 2023-08-11 12:50:35
                    [post_date_gmt] => 2023-08-11 12:50:35
                    [post_content] => 
                    [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-30 14:55:11
                    [post_modified_gmt] => 2023-08-30 14:55:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11000
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [122] => WP_Post Object
                (
                    [ID] => 10999
                    [post_author] => 5
                    [post_date] => 2023-08-11 11:3